51
|
Magnetic resonance imaging radiomics in categorizing ovarian masses and predicting clinical outcome: a preliminary study. Eur Radiol 2019; 29:3358-3371. [DOI: 10.1007/s00330-019-06124-9] [Citation(s) in RCA: 47] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2018] [Revised: 02/09/2019] [Accepted: 02/22/2019] [Indexed: 12/13/2022]
|
52
|
Elsherif SB, Faria SC, Lall C, Iyer R, Bhosale PR. Ovarian Cancer Genetics and Implications for Imaging and Therapy. J Comput Assist Tomogr 2019; 43:835-845. [DOI: 10.1097/rct.0000000000000932] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
53
|
Mihanfar A, Aghazadeh Attari J, Mohebbi I, Majidinia M, Kaviani M, Yousefi M, Yousefi B. Ovarian cancer stem cell: A potential therapeutic target for overcoming multidrug resistance. J Cell Physiol 2018; 234:3238-3253. [PMID: 30317560 DOI: 10.1002/jcp.26768] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2017] [Accepted: 04/27/2018] [Indexed: 12/24/2022]
Abstract
The cancer stem cell (CSC) model encompasses an advantageous paradigm that in recent decades provides a better elucidation for many important biological aspects of cancer initiation, progression, metastasis, and, more important, development of multidrug resistance (MDR). Such several other hematological malignancies and solid tumors and the identification and isolation of ovarian cancer stem cells (OV-CSCs) show that ovarian cancer also follows this hierarchical model. Gaining a better insight into CSC-mediated resistance holds promise for improving current ovarian cancer therapies and prolonging the survival of recurrent ovarian cancer patients in the future. Therefore, in this review, we will discuss some important mechanisms by which CSCs can escape chemotherapy, and then review the recent and growing body of evidence that supports the contribution of CSCs to MDR in ovarian cancer.
Collapse
Affiliation(s)
- Aynaz Mihanfar
- Faculty of Medicine, Department of Biochemistry, Urmia University of Medical Sciences, Urmia, Iran
| | | | - Iraj Mohebbi
- Department of Occupational Health, Urmia University of Medical Sciences, Urmia, Iran
| | - Maryam Majidinia
- Solid Tumor Research Center, Urmia University of Medical Sciences, Urmia, Iran
| | - Mojtaba Kaviani
- School of Nutrition and Dietetics, Acadia University, Wolfville, Nova Scotia, Canada
| | - Mehdi Yousefi
- Stem Cell and Regenerative Medicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Bahman Yousefi
- Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.,Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| |
Collapse
|
54
|
Chung YS, Lee JY, Kim HS, Nam EJ, Kim SW, Kim YT. Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience. Yonsei Med J 2018; 59:930-936. [PMID: 30187699 PMCID: PMC6127428 DOI: 10.3349/ymj.2018.59.8.930] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/25/2018] [Accepted: 08/09/2018] [Indexed: 02/06/2023] Open
Abstract
PURPOSE Outcomes in patients with ovarian high-grade serous carcinoma (HGSC) treated with neoadjuvant chemotherapy (NAC) have been widely studied; however, there is limited information on responses to chemotherapy among patients with non-HGSC. The aim of this study was to compare the survival outcomes of patients with advanced-stage non-HGSC and HGSC treated with NAC. MATERIALS AND METHODS This study was a retrospective analysis of patients with advanced-stage ovarian cancer treated at Yonsei Cancer Hospital between 2006 and 2017. The demographics, chemotherapy response, and survival rates were compared between patients with non-HGSC and those with HGSC. RESULTS Among 220 patients who underwent NAC, 25 (11.4%) patients had non-HGSC histologic subtypes, and all received a taxane-platinum combination regimen for NAC. Patients with non-HGSC had lower baseline cancer antigen-125 levels (p<0.001), poorer response rates (p<0.001), lower rates of optimal cytoreduction (p=0.003), and poorer progression-free survival (PFS) (median PFS 10.3 months vs. 18.3 months; p=0.009) and overall survival (OS) (median OS 25.5 months vs. 60.6 months; p<0.001), compared to those with HGSC. In multivariate analysis, non-HGSC was a negative prognostic factor for both PFS [hazard ratio (HR), 3.19; 95% confidence interval (CI), 1.73-5.88] and OS (HR, 4.22; 95% CI, 2.07-8.58). CONCLUSION In this study, poorer survival outcomes were observed in patients who underwent NAC for treatment of non-HGSC versus those treated for HGSC. Different treatment strategies are urgently required to improve survival outcomes for patients with non-HGSC undergoing NAC.
Collapse
Affiliation(s)
- Young Shin Chung
- Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea
| | - Jung Yun Lee
- Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea.
| | - Hyun Soo Kim
- Department of Pathology, Yonsei University College of Medicine, Seoul, Korea
| | - Eun Ji Nam
- Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea
| | - Sang Wun Kim
- Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea
| | - Young Tae Kim
- Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea
| |
Collapse
|
55
|
Can Stemness and Chemoresistance Be Therapeutically Targeted via Signaling Pathways in Ovarian Cancer? Cancers (Basel) 2018; 10:cancers10080241. [PMID: 30042330 PMCID: PMC6116003 DOI: 10.3390/cancers10080241] [Citation(s) in RCA: 44] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2018] [Revised: 07/12/2018] [Accepted: 07/17/2018] [Indexed: 12/12/2022] Open
Abstract
Ovarian cancer is the most lethal gynecological malignancy. Poor overall survival, particularly for patients with high grade serous (HGS) ovarian cancer, is often attributed to late stage at diagnosis and relapse following chemotherapy. HGS ovarian cancer is a heterogenous disease in that few genes are consistently mutated between patients. Additionally, HGS ovarian cancer is characterized by high genomic instability. For these reasons, personalized approaches may be necessary for effective treatment and cure. Understanding the molecular mechanisms that contribute to tumor metastasis and chemoresistance are essential to improve survival rates. One favored model for tumor metastasis and chemoresistance is the cancer stem cell (CSC) model. CSCs are cells with enhanced self-renewal properties that are enriched following chemotherapy. Elimination of this cell population is thought to be a mechanism to increase therapeutic response. Therefore, accurate identification of stem cell populations that are most clinically relevant is necessary. While many CSC identifiers (ALDH, OCT4, CD133, and side population) have been established, it is still not clear which population(s) will be most beneficial to target in patients. Therefore, there is a critical need to characterize CSCs with reliable markers and find their weaknesses that will make the CSCs amenable to therapy. Many signaling pathways are implicated for their roles in CSC initiation and maintenance. Therapeutically targeting pathways needed for CSC initiation or maintenance may be an effective way of treating HGS ovarian cancer patients. In conclusion, the prognosis for HGS ovarian cancer may be improved by combining CSC phenotyping with targeted therapies for pathways involved in CSC maintenance.
Collapse
|
56
|
Mukuda N, Fujii S, Inoue C, Fukunaga T, Oishi T, Harada T, Ogawa T. Bilateral Ovarian Tumors on MRI: How Should We Differentiate the Lesions? Yonago Acta Med 2018. [PMID: 29946217 DOI: 10.33160/yam.2018.06.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Background We investigated the distinguishing pathological features of bilateral ovarian tumors using magnetic resonance (MR) imaging. Methods Eighty-six patients with bilateral ovarian tumors on MR imaging were evaluated. The pathological diagnosis was investigated, and the results were subjected to statistical analysis using Mann-Whitney U test, Fisher's exact test, Chi-squared test and receiver operating characteristic (ROC) curve to determine the features useful for the differentiation of distinct types of lesions. Results The diagnosis of bilateral ovarian tumors was confirmed in eighty-one patients and the majority of the lesions were further classified into serous carcinoma (n = 36), mature teratoma (n = 20) and metastasis (n = 12). We assessed the existence of factors useful for the MR imaging differentiation between metastasis and serous carcinoma or primary malignant ovarian tumors. Cancer antigen (CA) 125 serum level and maximum tumor diameter were significantly different between metastasis and serous carcinoma and similarly, between metastasis and primary malignant ovarian tumors. MR imaging morphology, ascites and peritoneal implants did not show any significant difference between the different types of lesions. Conclusion Within our patient cohort, most bilateral ovarian tumor lesions were determined to be serous carcinoma, mature teratoma or metastasis. CA 125 serum level and maximum tumor diameter are useful markers for the differentiation between metastasis and serous carcinoma or primary malignant ovarian tumors.
Collapse
Affiliation(s)
- Naoko Mukuda
- Division of Radiology, Department of Pathophysiological and Therapeutic Science, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan
| | - Shinya Fujii
- Division of Radiology, Department of Pathophysiological and Therapeutic Science, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan
| | - Chie Inoue
- Division of Radiology, Department of Pathophysiological and Therapeutic Science, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan
| | - Takeru Fukunaga
- Division of Radiology, Department of Pathophysiological and Therapeutic Science, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan
| | - Tetsuro Oishi
- †Division of Reproductive-Perinatal Medicine and Gynecologic Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan
| | - Tasuku Harada
- †Division of Reproductive-Perinatal Medicine and Gynecologic Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan
| | - Toshihide Ogawa
- Division of Radiology, Department of Pathophysiological and Therapeutic Science, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan
| |
Collapse
|
57
|
A systematic approach to adnexal masses discovered on ultrasound: the ADNEx MR scoring system. Abdom Radiol (NY) 2018; 43:679-695. [PMID: 28900696 DOI: 10.1007/s00261-017-1272-7] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Adnexal lesions are a common occurrence in radiology practice and imaging plays a crucial role in triaging women appropriately. Current trends toward early detection and characterization have increased the need for accurate imaging assessment of adnexal lesions prior to treatment. Ultrasound is the first-line imaging modality for assessing adnexal lesions; however, approximately 20% of lesions are incompletely characterized after ultrasound evaluation. Secondary assessment with MR imaging using the ADNEx MR Scoring System has been demonstrated as highly accurate in the characterization of adnexal lesions and in excluding ovarian cancer. This review will address the role of MR imaging in further assessment of adnexal lesions discovered on US, and the utility of the ADNEx MR Scoring System.
Collapse
|
58
|
Xiao X, Dong D, He W, Song L, Wang Q, Yue J, Xie L. Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer. Gynecol Oncol 2018; 149:146-154. [PMID: 29496294 DOI: 10.1016/j.ygyno.2018.02.009] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2017] [Revised: 02/12/2018] [Accepted: 02/17/2018] [Indexed: 12/27/2022]
Abstract
OBJECTIVE The role of mismatch repair (MMR) deficiency in ovarian cancer (OC) pathogenesis and its association with other clinicopathologic features, such as microsatellite instability (MSI) and expression of checkpoint proteins, remain largely elusive. METHODS We performed Immunohistochemistry (IHC) for MLH1, MSH2, MSH6 and PMS2 on full-section slides from 419 OCs to assess the MMR status. The clinical relevance of MMR deficiency was analyzed in combination with clinical data. The MSI status (by MSI assay) and expression of CD3, CD8, PD-1 and PD-L1 (by IHC) were compared in OCs with different MMR status. RESULTS We found that 2.6% OCs were MMR-negative, 4.3% OCs were MMR-low, and 63.6% of MMR-negative OCs were of endometrioid subtype. A significantly higher proportion of MMR-negative OCs were diagnosed at stage I or II compared to MMR-proficient OCs (p=0.0041). MSI was observed in all tested MMR-negative OCs, 14.3% of tested MMR-low OCs and 3.2% of tested MMR-proficient OCs. In addition, MMR-negative OCs had better progression free survival compared to MMR-proficient and MMR-low OCs (p=0.0046). Furthermore, the majority of OCs were PD-1-positive in intratumoral lymphocytes regardless of MMR status; while MMR-negative OCs exhibited significantly increased CD3+ and CD8+ tumor-infiltrating lymphocytes, and PD-L1+ intratumoral immune cells compared to MMR-proficient OCs. CONCLUSION Our data suggests that MMR deficient OC is a unique molecular subgroup, characterized by early stage of diagnosis, MSI phenotype, and increased tumor-infiltrating lymphocytes. These patients may be good candidates for anti-PD-1/PD-L1 therapy.
Collapse
Affiliation(s)
- Xue Xiao
- Individualized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, 32 West Second Section, First Ring Road, Chengdu, Sichuan, China.
| | - Dandan Dong
- Department of Pathology, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, 32 West Second Section, First Ring Road, Chengdu, Sichuan, China
| | - Wenjing He
- Department of Gynecology and Obstetrics, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, 32 West Second Section, First Ring Road, Chengdu, Sichuan, China
| | - Linhong Song
- Department of Pathology, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, 32 West Second Section, First Ring Road, Chengdu, Sichuan, China
| | - Qiao Wang
- Department of Gynecology and Obstetrics, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, 32 West Second Section, First Ring Road, Chengdu, Sichuan, China
| | - Jun Yue
- Department of Gynecology and Obstetrics, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, 32 West Second Section, First Ring Road, Chengdu, Sichuan, China
| | - Lan Xie
- Department of Gynecology and Obstetrics, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, 32 West Second Section, First Ring Road, Chengdu, Sichuan, China.
| |
Collapse
|
59
|
Targeting estrogen receptor beta (ERβ) for treatment of ovarian cancer: importance of KDM6B and SIRT1 for ERβ expression and functionality. Oncogenesis 2018; 7:15. [PMID: 29422491 PMCID: PMC5833712 DOI: 10.1038/s41389-018-0027-9] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2017] [Revised: 11/21/2017] [Accepted: 12/25/2017] [Indexed: 02/06/2023] Open
Abstract
Estrogen receptor (ER) β has growth inhibitory and chemo drug potentiating effect on ovarian cancer cells. We studied the dependence of ERβ function on the presence of KDM6B and SIRT1 in human ovarian cancer cells in vitro. Activation of ERβ with the subtype-selective agonist KB9520 resulted in significant inhibition of human ovarian cancer cell growth. KB9520-activated ERβ had an additive effect on growth inhibition in combination with cisplatin and paclitaxel, respectively. Loss of KDM6B expression had a negative effect on ERβ function as a ligand-dependent inhibitor of ovarian cancer cell growth. In contrast, loss or inhibition of SIRT1 deacetylase activity restored ligand-activated ERβ functionality. Presented data suggest that selective targeting of ERβ with an agonist potentiate chemotherapy efficacy for the treatment of ovarian cancer and that downregulation or inhibition of SIRT1 may further enhance its therapeutic effect.
Collapse
|
60
|
Ueno M, Shiomi T, Mochizuki S, Chijiiwa M, Shimoda M, Kanai Y, Kataoka F, Hirasawa A, Susumu N, Aoki D, Okada Y. ADAM9 is over-expressed in human ovarian clear cell carcinomas and suppresses cisplatin-induced cell death. Cancer Sci 2018; 109:471-482. [PMID: 29247567 PMCID: PMC5797829 DOI: 10.1111/cas.13469] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2017] [Revised: 12/05/2017] [Accepted: 12/12/2017] [Indexed: 12/13/2022] Open
Abstract
ADAMs (a disintegrin and metalloproteinases) are involved in various biological events such as cell adhesion, migration and invasion, membrane protein shedding and proteolysis. However, there have been no systematic studies on the expression of ADAMs in human ovarian carcinomas. We therefore examined mRNA expression of all the proteolytic ADAM species including ADAM8, 9, 10, 12, 15, 17, 19, 20, 21, 28, 30, 33 and ADAMDEC1 in human ovarian carcinomas, and found that prototype membrane-anchored ADAM9m, but not secreted isoform ADAM9s, is significantly over-expressed in carcinomas than in control non-neoplastic ovarian tissue. Among the histological subtypes of serous, endometrioid, mucinous and clear cell carcinomas, ADAM9m expression was highest in clear cell carcinomas. Immunohistochemistry showed that all the clear cell carcinoma samples displayed ADAM9m primarily on the carcinoma cell membrane. By immunoblotting, ADAM9m was detected mainly in an active form in the clear cell carcinoma tissues. When two clear cell carcinoma cell lines (RMG-I and TOV21G cells) with ADAM9m expression were treated with cisplatin, viability was significantly reduced and apoptosis increased in ADAM9m knockdown cells compared with mock transfectants. In addition, treatment of the cells with neutralizing anti-ADAM9m antibody significantly decreased viability compared with non-immune IgG, whereas ADAM9m over-expression significantly increased viability compared with mock transfectants. Our data show, to the best of our knowledge, for the first time, that ADAM9m is over-expressed in an activated form in human ovarian clear cell carcinomas, and suggest that ADAM9m plays a key role in cisplatin resistance.
Collapse
Affiliation(s)
- Mari Ueno
- Department of Pathology, Keio University School of Medicine, Tokyo, Japan
| | - Takayuki Shiomi
- Department of Pathology, Keio University School of Medicine, Tokyo, Japan
| | - Satsuki Mochizuki
- Department of Pathology, Keio University School of Medicine, Tokyo, Japan
| | - Miyuki Chijiiwa
- Department of Pathology, Keio University School of Medicine, Tokyo, Japan
| | - Masayuki Shimoda
- Department of Pathology, Keio University School of Medicine, Tokyo, Japan
| | - Yae Kanai
- Department of Pathology, Keio University School of Medicine, Tokyo, Japan
| | - Fumio Kataoka
- Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
| | - Akira Hirasawa
- Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
| | - Nobuyuki Susumu
- Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
| | - Daisuke Aoki
- Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
| | - Yasunori Okada
- Department of Pathology, Keio University School of Medicine, Tokyo, Japan.,Department of Pathophysiology for Locomotive and Neoplastic Diseases, Juntendo University Graduate School of Medicine, Tokyo, Japan
| |
Collapse
|
61
|
Magge D, Ramalingam L, Shuai Y, Edwards RP, Pingpank JF, Ahrendt SS, Holtzman MP, Zeh HJ, Bartlett DL, Choudry HA. Hyperthermic intraperitoneal chemoperfusion as a component of multimodality therapy for ovarian and primary peritoneal cancer. J Surg Oncol 2017. [PMID: 28628712 DOI: 10.1002/jso.24666] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND AND OBJECTIVES The role of hyperthermic intraperitoneal chemoperfusion (HIPEC) in the multimodality treatment of ovarian peritoneal metastases (OPM) and primary peritoneal cancer (PPC) remains controversial. We hypothesized that cytoreductive surgery (CRS) and HIPEC would provide meaningful survival benefit without excessive morbidity. METHODS We reviewed clinicopathologic and perioperative data following 96 CRS-HIPEC procedures for primary or recurrent OPM and PPC. Kaplan-Meier survival curves and multivariate Cox-regression models identified prognostic factors affecting oncologic outcomes. RESULTS CRS-HIPEC was mostly performed for recurrent disease (56.3%) and high-grade serous carcinoma (72.9%). Platinum-based systemic chemotherapy was administered to 89.5% of patients, with 75.5% having platinum-sensitive disease at CRS-HIPEC. Complete macroscopic resection was achieved in 70.8% of patients. Clavien-Dindo grade 3/4 morbidity occurred in 23.4% of patients; three patients died within 60-days postoperatively. Median overall survival from diagnosis of peritoneal metastases and CRS-HIPEC was 78 and 38 months, respectively. Completeness of cytoreduction, pathologic subtype, and 30-day morbidity were independent predictors of survival in multiple regression analysis. CONCLUSIONS Our study demonstrates promising survival data and supports the role of HIPEC in the multimodality treatment algorithm for primary or recurrent OPM and PPC. However definite indications and timing of HIPEC need to be clarified by prospective studies.
Collapse
Affiliation(s)
- Deepa Magge
- Division of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Lekshmi Ramalingam
- Division of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Yongli Shuai
- The University of Pittsburgh Cancer Institute Biostatistics Facility, Pittsburgh, Pennsylvania
| | - Robert P Edwards
- Division of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh, Pittsburgh, Pennsylvania.,Department of Obstetrics and Gynecology, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - James F Pingpank
- Division of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Steven S Ahrendt
- Division of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Matthew P Holtzman
- Division of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Herbert J Zeh
- Division of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - David L Bartlett
- Division of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Haroon A Choudry
- Division of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh, Pittsburgh, Pennsylvania
| |
Collapse
|
62
|
BenTaieb A, Li-Chang H, Huntsman D, Hamarneh G. A structured latent model for ovarian carcinoma subtyping from histopathology slides. Med Image Anal 2017; 39:194-205. [PMID: 28521242 DOI: 10.1016/j.media.2017.04.008] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2016] [Revised: 04/15/2017] [Accepted: 04/27/2017] [Indexed: 11/25/2022]
Abstract
Accurate subtyping of ovarian carcinomas is an increasingly critical and often challenging diagnostic process. This work focuses on the development of an automatic classification model for ovarian carcinoma subtyping. Specifically, we present a novel clinically inspired contextual model for histopathology image subtyping of ovarian carcinomas. A whole slide image is modelled using a collection of tissue patches extracted at multiple magnifications. An efficient and effective feature learning strategy is used for feature representation of a tissue patch. The locations of salient, discriminative tissue regions are treated as latent variables allowing the model to explicitly ignore portions of the large tissue section that are unimportant for classification. These latent variables are considered in a structured formulation to model the contextual information represented from the multi-magnification analysis of tissues. A novel, structured latent support vector machine formulation is defined and used to combine information from multiple magnifications while simultaneously operating within the latent variable framework. The structural and contextual nature of our method addresses the challenges of intra-class variation and pathologists' workload, which are prevalent in histopathology image classification. Extensive experiments on a dataset of 133 patients demonstrate the efficacy and accuracy of the proposed method against state-of-the-art approaches for histopathology image classification. We achieve an average multi-class classification accuracy of 90%, outperforming existing works while obtaining substantial agreement with six clinicians tested on the same dataset.
Collapse
Affiliation(s)
- Aïcha BenTaieb
- Department of Computing Science, Medical Image Analysis Lab, Simon Fraser University, Burnaby, Canada.
| | - Hector Li-Chang
- Departments of Pathology and Laboratory Medicine and Obstetrics and Gynaecology, University of British Columbia, Vancouver, Canada
| | - David Huntsman
- Departments of Pathology and Laboratory Medicine and Obstetrics and Gynaecology, University of British Columbia, Vancouver, Canada
| | - Ghassan Hamarneh
- Department of Computing Science, Medical Image Analysis Lab, Simon Fraser University, Burnaby, Canada
| |
Collapse
|
63
|
Stein EB, Wasnik AP, Sciallis AP, Kamaya A, Maturen KE. MR Imaging-Pathologic Correlation in Ovarian Cancer. Magn Reson Imaging Clin N Am 2017; 25:545-562. [PMID: 28668159 DOI: 10.1016/j.mric.2017.03.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
There are many ovarian cancer subtypes, giving rise to a range of appearances at gross pathology and magnetic resonance (MR) imaging. Certain fundamental concepts at MR, arising from underlying tissue characteristics, can provide guidance to radiologists in suggesting a diagnosis. The ability of multiparametric MR to risk stratify ovarian masses can contribute substantially to clinical decision making and patient management.
Collapse
Affiliation(s)
- Erica B Stein
- Department of Radiology, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA; Department of Radiology, University of Pittsburgh Medical Center, 200 Lothrop Street, Pittsburgh, PA 15213, USA.
| | - Ashish P Wasnik
- Department of Radiology, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
| | - Andrew P Sciallis
- Department of Pathology, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
| | - Aya Kamaya
- Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA 94305, USA
| | - Katherine E Maturen
- Department of Radiology, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA; Department of Obstetrics & Gynecology, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
| |
Collapse
|
64
|
Yan C, Jiang Y, Wan Y, Zhang L, Liu J, Zhou S, Cheng W. Long noncoding RNA NBAT-1 suppresses tumorigenesis and predicts favorable prognosis in ovarian cancer. Onco Targets Ther 2017; 10:1993-2002. [PMID: 28435289 PMCID: PMC5388203 DOI: 10.2147/ott.s124645] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Long noncoding RNA (lncRNA) has been proven to be involved in many biological processes in ovarian cancer (OC). However, the mechanism still remains unknown. In this study, we screened significantly downregulated NBAT-1, which has been proven to play a significant role in breast cancer, clear cell renal cell carcinoma, and neuroblastoma, but not in OC, in two independent datasets with relatively more samples (GSE18520 and GSE38666) from Gene Expression Omnibus. We found that lncRNA NBAT-1 was obviously downregulated in OC tissue compared to normal ovarian tissue (P<0.001) which was free of OC, and the detected levels of NBAT-1 were associated with the International Federation of Gynecology and Obstetrics stage and tumor size guidelines. Moreover, it has been shown that lower levels of NBAT-1 predict poor outcomes of OC. In order to investigate the functional role of NBAT-1, pcDNA-NBAT-1 and empty vector were transfected into TOV112D and OVCAR-3 cell lines. Overexpressed NBAT-1 significantly inhibited cell proliferation, invasion, and migration in both TOV112D and OVCAR-3 cell lines. Finally, Western blot assay indicated that NBAT-1 may exert its function by targeting the ERK1/2 and AKT signaling pathways. In addition, tumor formation growth assay showed that overexpressed NBAT-1 significantly suppresses tumor growth in vivo. In conclusion, our study suggests that NBAT-1 acts as an anti-oncogene in the development of OC.
Collapse
Affiliation(s)
- Changsheng Yan
- Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University
| | - Yi Jiang
- Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University
| | - Yicong Wan
- Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University
| | - Lin Zhang
- Department of Obstetrics and Gynecology, Zhongda Hospital Affiliated to Southeast University, Medical School, Southeast University, Nanjing, Jiangsu, People's Republic of China
| | - Jinhui Liu
- Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University
| | - Shulin Zhou
- Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University
| | - Wenjun Cheng
- Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University
| |
Collapse
|
65
|
Wang F, Wang Y, Zhou Y, Liu C, Xie L, Zhou Z, Liang D, Shen Y, Yao Z, Liu J. Comparison between types I and II epithelial ovarian cancer using histogram analysis of monoexponential, biexponential, and stretched-exponential diffusion models. J Magn Reson Imaging 2017; 46:1797-1809. [PMID: 28379611 DOI: 10.1002/jmri.25722] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2016] [Accepted: 03/14/2017] [Indexed: 12/23/2022] Open
Abstract
PURPOSE To evaluate the utility of histogram analysis of monoexponential, biexponential, and stretched-exponential models to a dualistic model of epithelial ovarian cancer (EOC). MATERIALS AND METHODS Fifty-two patients with histopathologically proven EOC underwent preoperative magnetic resonance imaging (MRI) (including diffusion-weighted imaging [DWI] with 11 b-values) using a 3.0T system and were divided into two groups: types I and II. Apparent diffusion coefficient (ADC), true diffusion coefficient (D), pseudodiffusion coefficient (D*), perfusion fraction (f), distributed diffusion coefficient (DDC), and intravoxel water diffusion heterogeneity (α) histograms were obtained based on solid components of the entire tumor. The following metrics of each histogram were compared between two types: 1) mean; 2) median; 3) 10th percentile and 90th percentile. Conventional MRI morphological features were also recorded. RESULTS Significant morphological features for predicting EOC type were maximum diameter (P = 0.007), texture of lesion (P = 0.001), and peritoneal implants (P = 0.001). For ADC, D, f, DDC, and α, all metrics were significantly lower in type II than type I (P < 0.05). Mean, median, 10th, and 90th percentile of D* were not significantly different (P = 0.336, 0.154, 0.779, and 0.203, respectively). Most histogram metrics of ADC, D, and DDC had significantly higher area under the receiver operating characteristic curve values than those of f and α (P < 0.05) CONCLUSION: It is feasible to grade EOC by morphological features and three models with histogram analysis. ADC, D, and DDC have better performance than f and α; f and α may provide additional information. LEVEL OF EVIDENCE 4 Technical Efficacy: Stage 1 J. Magn. Reson. Imaging 2017;46:1797-1809.
Collapse
Affiliation(s)
- Feng Wang
- Department of Radiology, Peking University Third Hospital, Haidian District, Beijing, P.R. China
| | - Yuxiang Wang
- Department of Pathology, School of Basic Medical Science, Peking University Third Hospital, Peking University Health Science Center, Beijing, P.R. China
| | - Yan Zhou
- Department of Radiology, Peking University Third Hospital, Haidian District, Beijing, P.R. China
| | - Congrong Liu
- Department of Pathology, School of Basic Medical Science, Peking University Third Hospital, Peking University Health Science Center, Beijing, P.R. China
| | - Lizhi Xie
- GE Healthcare, MR Research China, Beijing, P.R. China
| | - Zhenyu Zhou
- GE Healthcare, MR Research China, Beijing, P.R. China
| | - Dong Liang
- Siemens Ltd., China, Chaoyang District, Beijing, P.R. China
| | - Yang Shen
- Department of Radiology, Peking University Third Hospital, Haidian District, Beijing, P.R. China
| | - Zhihang Yao
- Department of Radiology, Peking University Third Hospital, Haidian District, Beijing, P.R. China
| | - Jianyu Liu
- Department of Radiology, Peking University Third Hospital, Haidian District, Beijing, P.R. China
| |
Collapse
|
66
|
Hou S, Du P, Wang P, Wang C, Liu P, Liu H. Significance of MNK1 in prognostic prediction and chemotherapy development of epithelial ovarian cancer. Clin Transl Oncol 2017; 19:1107-1116. [PMID: 28332091 DOI: 10.1007/s12094-017-1646-x] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2016] [Accepted: 03/13/2017] [Indexed: 12/31/2022]
Abstract
BACKGROUND Ovarian cancer is the most lethal gynecologic malignancy worldwide with surgery as the only curative treatment. Long-term overall survival (OS) of ovarian cancer is far from satisfactory, even though significant improvement has been made in post-operative chemotherapy. One of the most important death cause is the chemoresistance due to consecutive chemotherapy. Therefore, understanding the molecular mechanisms involved in ovarian cancer development and identification of novel therapeutic targets are urgently required. METHODS Immunohistochemical (IHC) staining was used to explore the expression pattern of mitogen-activated protein kinase (MAPK)-interacting kinase 1 (MNK1) in tumor tissues from 138 epithelial ovarian cancer (EOC) patients. Clinicopathological data were subjected to Kaplan-Meier survival and Cox multivariate analyses to evaluate the prognostic value of MNK1 in EOC. Overexpression and silencing procedures were performed on OVCAR-5 cells to investigate the mechanisms of MNK1 in regulating EOC development. The anti-tumor effects of CGP57380, a specific MNK inhibitor, were examined by cell viability assay. RESULTS Higher MNK1 expression showed significant relationship with advanced FIGO stage and positive lymph node metastasis of EOC. Univariate and multivariate analyses revealed that MNK1 was an independent prognostic factor for OS of EOC patients. In vitro study demonstrated that MNK1 can promote cell proliferation through regulating the phosphorylation level of eukaryotic initiation factor 4E. In addition, inhibition of MNK1 by CGP57380 significantly down-regulated the OVCAR-5 cell viability. CONCLUSION High MNK1 expression in EOC tissues indicates poor clinical outcomes, and MNK1 can act as a potential target for novel chemotherapy development towards EOC.
Collapse
Affiliation(s)
- S Hou
- Department of Pharmacology, Yidu Central Hospital of Weifang Affiliated to Weifang Medical University, Weifang, 261000, Shandong, China
| | - P Du
- Department of Plastic Surgery, Yidu Central Hospital of Weifang Affiliated to Weifang Medical University, Weifang, 261000, Shandong, China
| | - P Wang
- Department of Pain Treatment, Qingzhou Hospital of Traditional Chinese Medicine, Weifang, 261000, Shandong, China
| | - C Wang
- Department of Reproductive Center, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, Sichuan, China
| | - P Liu
- Department of Burn and Plastic Surgery, Qilu Hospital Affiliated to Shandong University, 107 Wenhua Xi Road, Jinan, 250012, Shandong, China.
| | - H Liu
- Department of General Surgery, Qilu Hospital Affiliated to Shandong University, 107 Wenhua Xi Road, Jinan, 250012, Shandong, China.
| |
Collapse
|
67
|
Brasseur K, Gévry N, Asselin E. Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget 2017; 8:4008-4042. [PMID: 28008141 PMCID: PMC5354810 DOI: 10.18632/oncotarget.14021] [Citation(s) in RCA: 126] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2016] [Accepted: 11/30/2016] [Indexed: 02/06/2023] Open
Abstract
Gynecological cancers are known for being very aggressive at their advanced stages. Indeed, the survival rate of both ovarian and endometrial cancers is very low when diagnosed lately and the success rate of current chemotherapy regimens is not very efficient. One of the main reasons for this low success rate is the acquired chemoresistance of these cancers during their progression. The mechanisms responsible for this acquired chemoresistance are numerous, including efflux pumps, repair mechanisms, survival pathways (PI3K/AKT, MAPK, EGFR, mTOR, estrogen signaling) and tumor suppressors (P53 and Par-4). To overcome these resistances, a new type of therapy has emerged named targeted therapy. The principle of targeted therapy is simple, taking advantage of changes acquired in malignant cancer cells (receptors, proteins, mechanisms) by using compounds specifically targeting these, thus limiting their action on healthy cells. Targeted therapies are emerging and many clinical trials targeting these pathways, frequently involved in chemoresistance, have been tested on gynecological cancers. Despite some targets being less efficient than expected as mono-therapies, the combination of compounds seems to be the promising avenue. For instance, we demonstrate using ChIP-seq analysis that estrogen downregulate tumor suppressor Par-4 in hormone-dependent cells by directly binding to its DNA regulatory elements and inhibiting estrogen signaling could reinstate Par-4 apoptosis-inducing abilities. This review will focus on the chemoresistance mechanisms and the clinical trials of targeted therapies associated with these, specifically for endometrial and ovarian cancers.
Collapse
Affiliation(s)
- Kevin Brasseur
- Research Group in Cellular Signaling, Department of Medical Biology, Canada Research Chair in Molecular Gyneco-Oncology, Université du Québec à Trois-Rivières, Trois-Rivières, Québec, Canada
| | - Nicolas Gévry
- Département de Biologie, Faculté des Sciences, Université de Sherbrooke, Boulevard de l’Université, Sherbrooke, QC, Canada
| | - Eric Asselin
- Research Group in Cellular Signaling, Department of Medical Biology, Canada Research Chair in Molecular Gyneco-Oncology, Université du Québec à Trois-Rivières, Trois-Rivières, Québec, Canada
| |
Collapse
|
68
|
Diagnosis of Ovarian Carcinoma Histotype Based on Limited Sampling: A Prospective Study Comparing Cytology, Frozen Section, and Core Biopsies to Full Pathologic Examination. Int J Gynecol Pathol 2016; 34:517-27. [PMID: 26107565 DOI: 10.1097/pgp.0000000000000199] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Growing insights into the biological features and molecular underpinnings of ovarian cancer has prompted a shift toward histotype-specific treatments and clinical trials. As a result, the preoperative diagnosis of ovarian carcinomas based on small tissue sampling is rapidly gaining importance. The data on the accuracy of ovarian carcinoma histotype-specific diagnosis based on small tissue samples, however, remains very limited in the literature. Herein, we describe a prospective series of 30 ovarian tumors diagnosed using cytology, frozen section, core needle biopsy, and immunohistochemistry (p53, p16, WT1, HNF-1β, ARID1A, TFF3, vimentin, and PR). The accuracy of histotype diagnosis using each of these modalities was 52%, 81%, 85%, and 84% respectively, using the final pathology report as the reference standard. The accuracy of histotype diagnosis using the Calculator for Ovarian Subtype Prediction (COSP), which evaluates immunohistochemical stains independent of histopathologic features, was 85%. Diagnostic accuracy varied across histotype and was lowest for endometrioid carcinoma across all diagnostic modalities (54%). High-grade serous carcinomas were the most overdiagnosed on core needle biopsy (accounting for 45% of misdiagnoses) and clear cell carcinomas the most overdiagnosed on frozen section (accounting for 36% of misdiagnoses). On core needle biopsy, 2/30 (7%) cases had a higher grade lesion missed due to sampling limitations. In this study, we identify several challenges in the diagnosis of ovarian tumors based on limited tissue sampling. Recognition of these scenarios can help improve diagnostic accuracy as we move forward with histotype-specific therapeutic strategies.
Collapse
|
69
|
Cheng Z, Guo J, Chen L, Luo N, Yang W, Qu X. A long noncoding RNA AB073614 promotes tumorigenesis and predicts poor prognosis in ovarian cancer. Oncotarget 2016; 6:25381-9. [PMID: 26299803 PMCID: PMC4694838 DOI: 10.18632/oncotarget.4541] [Citation(s) in RCA: 75] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2015] [Accepted: 07/17/2015] [Indexed: 12/28/2022] Open
Abstract
Long noncoding RNA (lncRNA) profiles in ovarian cancer (OC) remain largely unknown. In the present study, we screened AB073614 as a new candidate lncRNA which promotes development of OC, in two independent datasets (GSE18521 and GSE38666) from the Gene Expression Omnibus (GEO). The level of AB073614 was then detected in 75 paired OC tissues and adjacent normal tissues by qRT-PCR. Results showed that AB073614 expression was significantly up-regulated in 85.3% (64/75) cancerous tissues compared with normal counterparts (P < 0.01). Further, the 5-year overall survival (OS) in OC patients with high expression of AB073614 was inferior to that with low expression (17.2 months vs 30.0 months, P = 0.0025). To investigate the functional role of AB073614, AB073614 siRNA was transfected into OC cell lines. Knockdown of AB073614 expression significantly inhibited cell proliferation and invasion, resulted in cell arrest in G1 phase of cell cycle and a dramatic increase of apoptosis, both in HO-8910 and OVCAR3 cells. In vivo experiment also revealed that knockdown AB073614 inhibited OVCAR3 cells proliferation. Finally, western blot assays indicated that lncRNA AB073614 may exert its function by targeting ERK1/2 and AKT-mediated signaling pathway. In conclusion, our study suggests that lncRNA AB073614 acts as a functional oncogene in OC development.
Collapse
Affiliation(s)
- Zhongping Cheng
- Department of Obstetrics and Gynecology, Yangpu Hospital, Tongji University School of Medicine, Shanghai, PR China.,Institute of Gynecological Minimally Invasive Medicine, Tongji University School of Medicine, Shanghai, PR China
| | - Jing Guo
- Department of Obstetrics and Gynecology, Yangpu Hospital, Tongji University School of Medicine, Shanghai, PR China.,Institute of Gynecological Minimally Invasive Medicine, Tongji University School of Medicine, Shanghai, PR China
| | - Li Chen
- Department of Obstetrics and Gynecology, Yangpu Hospital, Tongji University School of Medicine, Shanghai, PR China.,Institute of Gynecological Minimally Invasive Medicine, Tongji University School of Medicine, Shanghai, PR China
| | - Ning Luo
- Department of Obstetrics and Gynecology, Yangpu Hospital, Tongji University School of Medicine, Shanghai, PR China.,Institute of Gynecological Minimally Invasive Medicine, Tongji University School of Medicine, Shanghai, PR China
| | - Weihong Yang
- Department of Obstetrics and Gynecology, Yangpu Hospital, Tongji University School of Medicine, Shanghai, PR China.,Institute of Gynecological Minimally Invasive Medicine, Tongji University School of Medicine, Shanghai, PR China
| | - Xiaoyan Qu
- Department of Obstetrics and Gynecology, Yangpu Hospital, Tongji University School of Medicine, Shanghai, PR China.,Institute of Gynecological Minimally Invasive Medicine, Tongji University School of Medicine, Shanghai, PR China
| |
Collapse
|
70
|
Meissnitzer M, Forstner R. MRI of endometrium cancer - how we do it. Cancer Imaging 2016; 16:11. [PMID: 27157039 PMCID: PMC4860771 DOI: 10.1186/s40644-016-0069-1] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2016] [Accepted: 03/27/2016] [Indexed: 12/16/2022] Open
Abstract
Endometrial cancer is the most common malignancy of the female pelvis. New concepts in endometrial cancer treatment emphasize the value of MRI as a major predictor of lymph node metastasis and tumour recurrence. MRI findings aid in triaging patients for a more tailored therapeutic regimen.This review discusses the value of MRI in the preoperative assessment of endometrial cancer and provides a practical approach how to image and report endometrial cancer. Practical tips are provided how to increase the diagnostic accuracy in staging of endometrial cancer and how to avoid pitfalls.
Collapse
Affiliation(s)
- Matthias Meissnitzer
- Department of Radiology, Landeskliniken Salzburg, Paracelsus Medical University, Müllner Hauptstr. 48, 5020, Salzburg, Austria.
| | - Rosemarie Forstner
- Department of Radiology, Landeskliniken Salzburg, Paracelsus Medical University, Müllner Hauptstr. 48, 5020, Salzburg, Austria
| |
Collapse
|
71
|
Abstract
This review will make familiar with new concepts in ovarian cancer and their impact on radiological practice. Disseminated peritoneal spread and ascites are typical of the most common (70-80 %) cancer type, high-grade serous ovarian cancer. Other cancer subtypes differ in origin, precursors, and imaging features. Expert sonography allows excellent risk assessment in adnexal masses. Owing to its high specificity, complementary MRI improves characterization of indeterminate lesions. Major changes in the new FIGO staging classification include fusion of fallopian tube and primary ovarian cancer and the subcategory stage IIIA1 for retroperitoneal lymph node metastases only. Inguinal lymph nodes, cardiophrenic lymph nodes, and umbilical metastases are classified as distant metastases (stage IVB). In multidisciplinary conferences (MDC), CT has been used to predict the success of cytoreductive surgery. Resectability criteria have to be specified and agreed on in MDC. Limitations in detection of metastases may be overcome using advanced MRI techniques.
Collapse
Affiliation(s)
- Rosemarie Forstner
- />Department of Radiology, Landeskliniken Salzburg, Paracelsus Medical University, Müllner Hauptstr. 48, 5020 Salzburg, Austria
| | - Matthias Meissnitzer
- />Department of Radiology, Landeskliniken Salzburg, Paracelsus Medical University, Müllner Hauptstr. 48, 5020 Salzburg, Austria
| | - Teresa Margarida Cunha
- />Serviço de Radiologia, Instituto Português de Oncologia de Lisboa Francisco Gentil, Rua Prof. Lima Basto, 1099-023 Lisbon, Portugal
| |
Collapse
|
72
|
Foti PV, Attinà G, Spadola S, Caltabiano R, Farina R, Palmucci S, Zarbo G, Zarbo R, D'Arrigo M, Milone P, Ettorre GC. MR imaging of ovarian masses: classification and differential diagnosis. Insights Imaging 2016; 7:21-41. [PMID: 26671276 PMCID: PMC4729709 DOI: 10.1007/s13244-015-0455-4] [Citation(s) in RCA: 76] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2015] [Revised: 11/18/2015] [Accepted: 11/27/2015] [Indexed: 01/07/2023] Open
Abstract
OBJECTIVE We propose a Magnetic Resonance Imaging (MRI) guided approach to differential diagnosis of ovarian tumours based on morphological appearance. BACKGROUND Characterization of ovarian lesions is of great importance in order to plan adequate therapeutic procedures, and may influence patient's management. Optimal assessment of adnexal masses requires a multidisciplinary approach, based on physical examination, laboratory tests and imaging techniques. Primary ovarian tumours can be classified into three main categories according to tumour origin: epithelial, germ cell and sex cord-stromal tumours. Ovarian neoplasms may be benign, borderline or malignant. Using an imaging-guided approach based on morphological appearance, we classified adnexal masses into four main groups: unilocular cyst, multilocular cyst, cystic and solid, predominantly solid. We describe MR signal intensity features and enhancement behaviour of ovarian lesions using pathologically proven examples from our institution. CONCLUSION MRI is an essential problem-solving tool to determine the site of origin of a pelvic mass, to characterize an adnexal mass, and to detect local invasion. The main advantages of MRI are the high contrast resolution and lack of ionizing radiation exposure. Although different pathological conditions may show similar radiologic manifestations, radiologists should be aware of MRI features of ovarian lesions that may orientate differential diagnosis. TEACHING POINTS • Diagnostic imaging plays a crucial role in detection, characterization and staging of adnexal masses. • Characterization of an ovarian lesion may influence patient's management. • Different pathological conditions may have similar radiologic manifestations. • Non-neoplastic lesions should always be taken into consideration.
Collapse
Affiliation(s)
- Pietro Valerio Foti
- Radiodiagnostic and Radiotherapy Unit, University Hospital "Policlinico-Vittorio Emanuele", Via Santa Sofia 78, 95123, Catania, Italy.
| | - Giancarlo Attinà
- Radiodiagnostic and Radiotherapy Unit, University Hospital "Policlinico-Vittorio Emanuele", Via Santa Sofia 78, 95123, Catania, Italy
| | - Saveria Spadola
- Department G.F. Ingrassia - Institute of Pathology, University of Catania, Catania, Italy
| | - Rosario Caltabiano
- Department G.F. Ingrassia - Institute of Pathology, University of Catania, Catania, Italy
| | - Renato Farina
- Radiodiagnostic and Radiotherapy Unit, University Hospital "Policlinico-Vittorio Emanuele", Via Santa Sofia 78, 95123, Catania, Italy
| | - Stefano Palmucci
- Radiodiagnostic and Radiotherapy Unit, University Hospital "Policlinico-Vittorio Emanuele", Via Santa Sofia 78, 95123, Catania, Italy
| | - Giuseppe Zarbo
- Department of General Surgery and Medical-Surgical Specialties - Institute of Obstetrics and Ginecology, University of Catania, Catania, Italy
| | - Rosario Zarbo
- Department of General Surgery and Medical-Surgical Specialties - Institute of Obstetrics and Ginecology, University of Catania, Catania, Italy
| | - Maria D'Arrigo
- Pathology Unit, University Hospital "Policlinico-Vittorio Emanuele", Catania, Italy
| | - Pietro Milone
- Radiodiagnostic and Radiotherapy Unit, University Hospital "Policlinico-Vittorio Emanuele", Via Santa Sofia 78, 95123, Catania, Italy
| | - Giovanni Carlo Ettorre
- Radiodiagnostic and Radiotherapy Unit, University Hospital "Policlinico-Vittorio Emanuele", Via Santa Sofia 78, 95123, Catania, Italy
| |
Collapse
|
73
|
Anglesio MS, Wang YK, Maassen M, Horlings HM, Bashashati A, Senz J, Mackenzie R, Grewal DS, Li-Chang H, Karnezis AN, Sheffield BS, McConechy MK, Kommoss F, Taran FA, Staebler A, Shah SP, Wallwiener D, Brucker S, Gilks CB, Kommoss S, Huntsman DG. Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality. J Natl Cancer Inst 2016; 108:djv428. [PMID: 26832771 DOI: 10.1093/jnci/djv428] [Citation(s) in RCA: 96] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2015] [Accepted: 12/14/2015] [Indexed: 01/14/2023] Open
Abstract
Many women with ovarian endometrioid carcinoma present with concurrent endometrial carcinoma. Organ-confined and low-grade synchronous endometrial and ovarian tumors (SEOs) clinically behave as independent primary tumors rather than a single advanced-stage carcinoma. We used 18 SEOs to investigate the ancestral relationship between the endometrial and ovarian components. Based on both targeted and exome sequencing, 17 of 18 patient cases of simultaneous cancer of the endometrium and ovary from our series showed evidence of a clonal relationship, ie, primary tumor and metastasis. Eleven patient cases fulfilled clinicopathological criteria that would lead to classification as independent endometrial and ovarian primary carcinomas, including being of FIGO stage T1a/1A, with organ-restricted growth and without surface involvement; 10 of 11 of these cases showed evidence of clonality. Our observations suggest that the disseminating cells amongst SEOs are restricted to physically accessible and microenvironment-compatible sites yet remain indolent, without the capacity for further dissemination.
Collapse
Affiliation(s)
- Michael S Anglesio
- Department of Pathology and Laboratory Medicine, (MSA, HMH, JS, HLC, ANK, BSS, MKM, CBG, SK, DGH) and Department of Obstetrics and Gynaecology (MSA, DGH), University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, British Columbia Cancer Agency Cancer Research Centre, Vancouver, Canada (YKW, AB, RM, DSG, SPS); Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany (MM, FAT, DW, SB, SK); Division of Anatomic Pathology, Synlab MVZ, Institute of Pathology, Mannheim, Germany (FK); Division of Gynecologic Pathology, Institute of Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany (AS); Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, Canada (CBG)
| | - Yi Kan Wang
- Department of Pathology and Laboratory Medicine, (MSA, HMH, JS, HLC, ANK, BSS, MKM, CBG, SK, DGH) and Department of Obstetrics and Gynaecology (MSA, DGH), University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, British Columbia Cancer Agency Cancer Research Centre, Vancouver, Canada (YKW, AB, RM, DSG, SPS); Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany (MM, FAT, DW, SB, SK); Division of Anatomic Pathology, Synlab MVZ, Institute of Pathology, Mannheim, Germany (FK); Division of Gynecologic Pathology, Institute of Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany (AS); Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, Canada (CBG)
| | - Madlen Maassen
- Department of Pathology and Laboratory Medicine, (MSA, HMH, JS, HLC, ANK, BSS, MKM, CBG, SK, DGH) and Department of Obstetrics and Gynaecology (MSA, DGH), University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, British Columbia Cancer Agency Cancer Research Centre, Vancouver, Canada (YKW, AB, RM, DSG, SPS); Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany (MM, FAT, DW, SB, SK); Division of Anatomic Pathology, Synlab MVZ, Institute of Pathology, Mannheim, Germany (FK); Division of Gynecologic Pathology, Institute of Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany (AS); Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, Canada (CBG)
| | - Hugo M Horlings
- Department of Pathology and Laboratory Medicine, (MSA, HMH, JS, HLC, ANK, BSS, MKM, CBG, SK, DGH) and Department of Obstetrics and Gynaecology (MSA, DGH), University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, British Columbia Cancer Agency Cancer Research Centre, Vancouver, Canada (YKW, AB, RM, DSG, SPS); Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany (MM, FAT, DW, SB, SK); Division of Anatomic Pathology, Synlab MVZ, Institute of Pathology, Mannheim, Germany (FK); Division of Gynecologic Pathology, Institute of Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany (AS); Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, Canada (CBG)
| | - Ali Bashashati
- Department of Pathology and Laboratory Medicine, (MSA, HMH, JS, HLC, ANK, BSS, MKM, CBG, SK, DGH) and Department of Obstetrics and Gynaecology (MSA, DGH), University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, British Columbia Cancer Agency Cancer Research Centre, Vancouver, Canada (YKW, AB, RM, DSG, SPS); Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany (MM, FAT, DW, SB, SK); Division of Anatomic Pathology, Synlab MVZ, Institute of Pathology, Mannheim, Germany (FK); Division of Gynecologic Pathology, Institute of Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany (AS); Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, Canada (CBG)
| | - Janine Senz
- Department of Pathology and Laboratory Medicine, (MSA, HMH, JS, HLC, ANK, BSS, MKM, CBG, SK, DGH) and Department of Obstetrics and Gynaecology (MSA, DGH), University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, British Columbia Cancer Agency Cancer Research Centre, Vancouver, Canada (YKW, AB, RM, DSG, SPS); Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany (MM, FAT, DW, SB, SK); Division of Anatomic Pathology, Synlab MVZ, Institute of Pathology, Mannheim, Germany (FK); Division of Gynecologic Pathology, Institute of Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany (AS); Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, Canada (CBG)
| | - Robertson Mackenzie
- Department of Pathology and Laboratory Medicine, (MSA, HMH, JS, HLC, ANK, BSS, MKM, CBG, SK, DGH) and Department of Obstetrics and Gynaecology (MSA, DGH), University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, British Columbia Cancer Agency Cancer Research Centre, Vancouver, Canada (YKW, AB, RM, DSG, SPS); Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany (MM, FAT, DW, SB, SK); Division of Anatomic Pathology, Synlab MVZ, Institute of Pathology, Mannheim, Germany (FK); Division of Gynecologic Pathology, Institute of Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany (AS); Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, Canada (CBG)
| | - Diljot S Grewal
- Department of Pathology and Laboratory Medicine, (MSA, HMH, JS, HLC, ANK, BSS, MKM, CBG, SK, DGH) and Department of Obstetrics and Gynaecology (MSA, DGH), University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, British Columbia Cancer Agency Cancer Research Centre, Vancouver, Canada (YKW, AB, RM, DSG, SPS); Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany (MM, FAT, DW, SB, SK); Division of Anatomic Pathology, Synlab MVZ, Institute of Pathology, Mannheim, Germany (FK); Division of Gynecologic Pathology, Institute of Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany (AS); Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, Canada (CBG)
| | - Hector Li-Chang
- Department of Pathology and Laboratory Medicine, (MSA, HMH, JS, HLC, ANK, BSS, MKM, CBG, SK, DGH) and Department of Obstetrics and Gynaecology (MSA, DGH), University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, British Columbia Cancer Agency Cancer Research Centre, Vancouver, Canada (YKW, AB, RM, DSG, SPS); Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany (MM, FAT, DW, SB, SK); Division of Anatomic Pathology, Synlab MVZ, Institute of Pathology, Mannheim, Germany (FK); Division of Gynecologic Pathology, Institute of Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany (AS); Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, Canada (CBG)
| | - Anthony N Karnezis
- Department of Pathology and Laboratory Medicine, (MSA, HMH, JS, HLC, ANK, BSS, MKM, CBG, SK, DGH) and Department of Obstetrics and Gynaecology (MSA, DGH), University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, British Columbia Cancer Agency Cancer Research Centre, Vancouver, Canada (YKW, AB, RM, DSG, SPS); Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany (MM, FAT, DW, SB, SK); Division of Anatomic Pathology, Synlab MVZ, Institute of Pathology, Mannheim, Germany (FK); Division of Gynecologic Pathology, Institute of Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany (AS); Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, Canada (CBG)
| | - Brandon S Sheffield
- Department of Pathology and Laboratory Medicine, (MSA, HMH, JS, HLC, ANK, BSS, MKM, CBG, SK, DGH) and Department of Obstetrics and Gynaecology (MSA, DGH), University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, British Columbia Cancer Agency Cancer Research Centre, Vancouver, Canada (YKW, AB, RM, DSG, SPS); Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany (MM, FAT, DW, SB, SK); Division of Anatomic Pathology, Synlab MVZ, Institute of Pathology, Mannheim, Germany (FK); Division of Gynecologic Pathology, Institute of Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany (AS); Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, Canada (CBG)
| | - Melissa K McConechy
- Department of Pathology and Laboratory Medicine, (MSA, HMH, JS, HLC, ANK, BSS, MKM, CBG, SK, DGH) and Department of Obstetrics and Gynaecology (MSA, DGH), University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, British Columbia Cancer Agency Cancer Research Centre, Vancouver, Canada (YKW, AB, RM, DSG, SPS); Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany (MM, FAT, DW, SB, SK); Division of Anatomic Pathology, Synlab MVZ, Institute of Pathology, Mannheim, Germany (FK); Division of Gynecologic Pathology, Institute of Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany (AS); Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, Canada (CBG)
| | - Friedrich Kommoss
- Department of Pathology and Laboratory Medicine, (MSA, HMH, JS, HLC, ANK, BSS, MKM, CBG, SK, DGH) and Department of Obstetrics and Gynaecology (MSA, DGH), University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, British Columbia Cancer Agency Cancer Research Centre, Vancouver, Canada (YKW, AB, RM, DSG, SPS); Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany (MM, FAT, DW, SB, SK); Division of Anatomic Pathology, Synlab MVZ, Institute of Pathology, Mannheim, Germany (FK); Division of Gynecologic Pathology, Institute of Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany (AS); Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, Canada (CBG)
| | - Florin A Taran
- Department of Pathology and Laboratory Medicine, (MSA, HMH, JS, HLC, ANK, BSS, MKM, CBG, SK, DGH) and Department of Obstetrics and Gynaecology (MSA, DGH), University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, British Columbia Cancer Agency Cancer Research Centre, Vancouver, Canada (YKW, AB, RM, DSG, SPS); Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany (MM, FAT, DW, SB, SK); Division of Anatomic Pathology, Synlab MVZ, Institute of Pathology, Mannheim, Germany (FK); Division of Gynecologic Pathology, Institute of Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany (AS); Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, Canada (CBG)
| | - Annette Staebler
- Department of Pathology and Laboratory Medicine, (MSA, HMH, JS, HLC, ANK, BSS, MKM, CBG, SK, DGH) and Department of Obstetrics and Gynaecology (MSA, DGH), University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, British Columbia Cancer Agency Cancer Research Centre, Vancouver, Canada (YKW, AB, RM, DSG, SPS); Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany (MM, FAT, DW, SB, SK); Division of Anatomic Pathology, Synlab MVZ, Institute of Pathology, Mannheim, Germany (FK); Division of Gynecologic Pathology, Institute of Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany (AS); Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, Canada (CBG)
| | - Sohrab P Shah
- Department of Pathology and Laboratory Medicine, (MSA, HMH, JS, HLC, ANK, BSS, MKM, CBG, SK, DGH) and Department of Obstetrics and Gynaecology (MSA, DGH), University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, British Columbia Cancer Agency Cancer Research Centre, Vancouver, Canada (YKW, AB, RM, DSG, SPS); Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany (MM, FAT, DW, SB, SK); Division of Anatomic Pathology, Synlab MVZ, Institute of Pathology, Mannheim, Germany (FK); Division of Gynecologic Pathology, Institute of Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany (AS); Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, Canada (CBG)
| | - Diethelm Wallwiener
- Department of Pathology and Laboratory Medicine, (MSA, HMH, JS, HLC, ANK, BSS, MKM, CBG, SK, DGH) and Department of Obstetrics and Gynaecology (MSA, DGH), University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, British Columbia Cancer Agency Cancer Research Centre, Vancouver, Canada (YKW, AB, RM, DSG, SPS); Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany (MM, FAT, DW, SB, SK); Division of Anatomic Pathology, Synlab MVZ, Institute of Pathology, Mannheim, Germany (FK); Division of Gynecologic Pathology, Institute of Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany (AS); Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, Canada (CBG)
| | - Sara Brucker
- Department of Pathology and Laboratory Medicine, (MSA, HMH, JS, HLC, ANK, BSS, MKM, CBG, SK, DGH) and Department of Obstetrics and Gynaecology (MSA, DGH), University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, British Columbia Cancer Agency Cancer Research Centre, Vancouver, Canada (YKW, AB, RM, DSG, SPS); Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany (MM, FAT, DW, SB, SK); Division of Anatomic Pathology, Synlab MVZ, Institute of Pathology, Mannheim, Germany (FK); Division of Gynecologic Pathology, Institute of Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany (AS); Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, Canada (CBG)
| | - C Blake Gilks
- Department of Pathology and Laboratory Medicine, (MSA, HMH, JS, HLC, ANK, BSS, MKM, CBG, SK, DGH) and Department of Obstetrics and Gynaecology (MSA, DGH), University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, British Columbia Cancer Agency Cancer Research Centre, Vancouver, Canada (YKW, AB, RM, DSG, SPS); Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany (MM, FAT, DW, SB, SK); Division of Anatomic Pathology, Synlab MVZ, Institute of Pathology, Mannheim, Germany (FK); Division of Gynecologic Pathology, Institute of Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany (AS); Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, Canada (CBG)
| | - Stefan Kommoss
- Department of Pathology and Laboratory Medicine, (MSA, HMH, JS, HLC, ANK, BSS, MKM, CBG, SK, DGH) and Department of Obstetrics and Gynaecology (MSA, DGH), University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, British Columbia Cancer Agency Cancer Research Centre, Vancouver, Canada (YKW, AB, RM, DSG, SPS); Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany (MM, FAT, DW, SB, SK); Division of Anatomic Pathology, Synlab MVZ, Institute of Pathology, Mannheim, Germany (FK); Division of Gynecologic Pathology, Institute of Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany (AS); Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, Canada (CBG)
| | - David G Huntsman
- Department of Pathology and Laboratory Medicine, (MSA, HMH, JS, HLC, ANK, BSS, MKM, CBG, SK, DGH) and Department of Obstetrics and Gynaecology (MSA, DGH), University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, British Columbia Cancer Agency Cancer Research Centre, Vancouver, Canada (YKW, AB, RM, DSG, SPS); Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany (MM, FAT, DW, SB, SK); Division of Anatomic Pathology, Synlab MVZ, Institute of Pathology, Mannheim, Germany (FK); Division of Gynecologic Pathology, Institute of Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany (AS); Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, Canada (CBG).
| |
Collapse
|
74
|
Theophilou G, Lima KMG, Martin-Hirsch PL, Stringfellow HF, Martin FL. ATR-FTIR spectroscopy coupled with chemometric analysis discriminates normal, borderline and malignant ovarian tissue: classifying subtypes of human cancer. Analyst 2016; 141:585-594. [DOI: 10.1039/c5an00939a] [Citation(s) in RCA: 62] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023]
Abstract
Spectrochemical discrimination of ovarian cancer.
Collapse
Affiliation(s)
| | | | | | - Helen F. Stringfellow
- Department of Obstetrics and Gynaecology
- Central Lancashire Teaching Hospitals NHS Foundation Trust
- Preston
- UK
| | | |
Collapse
|
75
|
Saida T, Tanaka YO, Matsumoto K, Satoh T, Yoshikawa H, Minami M. Revised FIGO staging system for cancer of the ovary, fallopian tube, and peritoneum: important implications for radiologists. Jpn J Radiol 2015; 34:117-24. [PMID: 26696400 DOI: 10.1007/s11604-015-0513-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2015] [Accepted: 12/08/2015] [Indexed: 12/17/2022]
Abstract
Ovarian cancer is the seventh most common cancer diagnosis among women worldwide. The International Federation of Gynecology and Obstetrics recently significantly revised staging criteria for cancer of the ovary. The latest revision was based on the concept that high-grade serous tubal intraepithelial carcinoma (STIC) may be the origin of some high-grade serous carcinomas of the ovary and peritoneum. Therefore, staging criteria for the ovary, fallopian tube, and peritoneum have been unified. Understanding this background and other important revised points are essential for radiologists concerned with imaging diagnosis in gynecologic oncology. Through this review, we introduce the STIC theory and show examples of diseases in accordance with the new staging criteria based on magnetic resonance imaging (MRI) and computed tomography (CT) results.
Collapse
Affiliation(s)
- Tsukasa Saida
- Department of Radiology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
| | - Yumiko Oishi Tanaka
- Department of Radiology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan
| | - Koji Matsumoto
- Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan
| | - Toyomi Satoh
- Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan
| | - Hiroyuki Yoshikawa
- Obstetrics and Gynecology, Ibaraki Prefectural Central Hospital, Koibuchi 6528, Kasama, Ibaraki, 309-1793, Japan
| | - Manabu Minami
- Department of Radiology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan
| |
Collapse
|
76
|
Neto N, Cunha TM. Do hereditary syndrome-related gynecologic cancers have any specific features? Insights Imaging 2015; 6:545-52. [PMID: 26337050 PMCID: PMC4569599 DOI: 10.1007/s13244-015-0425-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2015] [Revised: 07/20/2015] [Accepted: 07/29/2015] [Indexed: 12/21/2022] Open
Abstract
Abstract Hereditary syndromes are responsible for 10 % of gynaecologic cancers, among which hereditary breast-ovarian cancer and hereditary non-polyposis colon cancer syndromes, known as HBOC and Lynch syndromes respectively, present the highest relative risk. The latter predisposes to endometrial cancer and both contribute to ovarian cancer. Cowden syndrome-related endometrial cancer and the increased risk of ovarian, uterine and cervical cancers associated with Peutz-Jeghers syndrome, are also demonstrated, while Li-Fraumeni syndrome patients are prone to develop ovarian and endometrial cancers. Despite these syndromes’ susceptibility to gynaecologic cancers being consensual, it is still not clear whether these tumours have any epidemiologic, clinical, pathologic or imaging specific features that could allow any of the intervening physicians to raise suspicion of a hereditary syndrome in patients without known genetic risk. Moreover, controversy exists regarding both screening and surveillance schemes. Our literature review provides an updated perspective on the evidence-based specific features of tumours related to each of these syndromes as well as on the most accepted screening and surveillance guidelines. In addition, some illustrative cases are presented. Teaching Points • HBOC syndrome is mainly associated with ovarian HGSC, which arises in fallopian fimbriae. • LS-related endometrial tumours show histological diversity and predilection for lower uterine segment. • LS and CS-related ovarian cancers are mostly of non-serous type, usually endometrioid. • Ovarian SCTAT and cervical adenoma malignum are strongly associated with PJS. • Unfortunately, hereditary gynaecologic cancers do not seem to have distinctive imaging features.
Collapse
Affiliation(s)
- Nelson Neto
- Radiology Department, Centro Hospitalar de Lisboa Ocidental, Estrada do Forte do Alto do Duque, 1449-005, Lisboa, Portugal.
| | - Teresa Margarida Cunha
- Radiology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Rua Professor Lima Basto, 1009-023, Lisboa, Portugal
| |
Collapse
|
77
|
Magnetic Resonance Imaging Characteristics of Ovarian Clear Cell Carcinoma. PLoS One 2015; 10:e0132406. [PMID: 26161555 PMCID: PMC4498632 DOI: 10.1371/journal.pone.0132406] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2014] [Accepted: 06/14/2015] [Indexed: 01/25/2023] Open
Abstract
PURPOSE To probe the magnetic resonance imaging (MRI) features of ovarian clear cell carcinoma (OCCC). METHODS This study retrospectively collected MRI data for 21 pathology-confirmed OCCCs from 19 female patients. The MRI findings were analyzed to determine the tumor size, shape/edge, shape and number of protrusions within the cyst, cystic or necrotic components, signal intensity (SI) and enhancement features. RESULTS The age of the 19 patients ranged from 28 to 63 years (mean age: 53 years). Unilateral tumors were found in 17 patients (17/19, 89%); the average size of all tumors was 10.8 cm. The tumors on MRI were classified into two categories: (a) "cystic adnexal mass with solid protrusions" in 12 (57%) and (b) "solid adnexal mass with cystic areas or necrosis" in 9 (43%). For group a, high to very high SI was observed for most tumors (10/12, 83%) on T1-weighted images (T1WIs), and very high SI was observed on T2-weighted images (T2WIs) for all 12 tumors. Most solid protrusions were irregular and few in number and exhibited heterogeneous intermediate SI on T1WIs and T2WIs and prolonged enhanced SI in the contrast study. All 9 OCCCs in group b were predominantly solid masses with unequally sized necrotic or cystic areas in which some cysts were located at the periphery of the tumor (4/9, 44%). The solid components in all 9 tumors showed iso- or slightly high SI on T1WIs, heterogeneous iso-high SI on T2WIs and heterogeneous prolonged enhancement. According to FIGO classification, 14 tumors (14/19, 74%) were stages I-II, and 5 (5/19, 26%) were stages III-IV. CONCLUSIONS On MRI, OCCCs present as large unilateral multilocular or unilocular cystic masses with irregular intermediate SI solid protrusions or predominantly solid masses with cysts or necrosis at an early FIGO stage.
Collapse
|
78
|
Kobayashi H, Sugimoto H, Onishi S, Nakano K. Novel biomarker candidates for the diagnosis of ovarian clear cell carcinoma. Oncol Lett 2015; 10:612-618. [PMID: 26622542 DOI: 10.3892/ol.2015.3367] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2014] [Accepted: 05/27/2015] [Indexed: 02/07/2023] Open
Abstract
Ovarian clear cell carcinoma can arise from endometriosis; however, it is distinct from other types of epithelial ovarian carcinoma in terms of its clinicopathological and molecular features. Cancer antigen 125 lacks the sensitivity and specificity required for accurate clinical diagnosis of clear cell carcinoma. Therefore, the aim of the current review was to identify novel biomarker candidates for the immunohistochemical and serological diagnosis of clear cell carcinoma. A search of the relevant English language literature published between 1966 and 2014 was conducted using the PubMed MEDLINE online database. High-throughput tissue microarray technology and proteomic screening combined with mass spectrometry may provide additional information regarding diagnostic biomarker candidates for ovarian clear cell carcinoma. The present review summarizes the characteristics of potential genomic alterations that activate cancer signaling pathways and, thus, contribute to carcinogenesis. The major signaling pathways activated in clear cell carcinoma are associated with cell cycle regulation (hepatitis A virus cellular receptor 1 and tumor protein D52), growth factor signaling (insulin-like growth factor binding protein 1; KiSS-1 metastasis-suppressor; erb-b2 receptor tyrosine kinase 2; and fibroblast growth factor receptor 2), anti-apoptosis and survival pathways [sialidase 3 (membrane sialidase)], metabolism (γ-glutamyltransferase 1), chemoresistance (napsin A aspartic peptidase, glutathione peroxidase 3; and aldehyde dehydrogenase 1 family, member A1), coagulation [coagulation factor III (thromboplastin, tissue factor); and tissue factor pathway inhibitor 2], signaling (lectin, galactoside-binding and soluble, 3), and adhesion and the extracellular matrix [cadherin 1, type 1, E-cadherin (epithelial); versican; and laminin, α 5]. The present review of the relevant literature may provide a basis for additional clinical investigation of the ovarian clear cell carcinoma serum biomarker candidate proteins identified herein.
Collapse
Affiliation(s)
- Hiroshi Kobayashi
- Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, Nara 634-8522, Japan
| | - Hitomi Sugimoto
- Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, Nara 634-8522, Japan
| | - Shunsuke Onishi
- Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, Nara 634-8522, Japan
| | - Kazutoshi Nakano
- Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, Nara 634-8522, Japan
| |
Collapse
|
79
|
Li HM, Qiang JW, Xia GL, Zhao SH, Ma FH, Cai SQ, Feng F, Fu AY. MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma. J Ovarian Res 2015; 8:26. [PMID: 25926038 PMCID: PMC4422148 DOI: 10.1186/s13048-015-0154-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2015] [Accepted: 04/23/2015] [Indexed: 01/25/2023] Open
Abstract
PURPOSE To investigate magnetic resonance imaging (MRI) features for differentiating ovarian endometrioid adenocarcinoma (OEC) from high-grade serous adenocarcinoma (HGSC). MATERIALS AND METHODS Twenty-three patients with 25 OECs and 93 patients with 139 HGSCs confirmed by surgery and pathology underwent conventional MRI and diffusion-weighted imaging (DWI). The MRI features of the tumors, including laterality, size, shape, configuration, signal intensity, ADC value of solid component, enhancement, ascites, synchronous primary cancer (SPC) of the ovary and endometrium, and clinical stage, were evaluated and compared between two groups. RESULTS The following characteristics were significantly more common for OECs than HGSCs: unilateral (91.3% vs 50.5%, P < 0.001), larger mass (80.0% vs 48.2%, P = 0.005), round or oval shape (64.0% vs 17.3%, P < 0.001), mainly cystic with mural nodules or papillary projections (72.0% vs 18.7%, P < 0.001), cystic component with homogeneous iso- or hyperintensity on T1WI (82.6% vs 4.3%, P < 0.001), moderate enhancement (52.0% vs 26.6%, P = 0.011), no or mild ascites (91.3% vs 57.0%, P = 0.002), and SPC (43.5% vs 4.3%, P < 0.001). The ADC value of the solid component was higher in OECs (0.979 ± 0.197 × 10(-3) mm(2)/s) than in HGSCs (0.820 ± 0.112 × 10(-3) mm(2)/s) (P = 0.002). When a mainly cystic mass with mural nodules or papillary projections was associated with any one of homogeneously iso- or hyperintense cystic component on TIWI, a relatively higher ADC value and SPC, the sensitivity, specificity, accuracy, and positive and negative predictive values for characterizing OEC were 87.0%, 93.5%, 92.2%, 76.9%, and 96.7%, respectively. CONCLUSIONS Conventional MRI combining DWI is helpful for differentiating OECs from HGSCs.
Collapse
Affiliation(s)
- Hai Ming Li
- Department of Radiology, Jinshan Hospital, Shanghai Medical College, Fudan University, 1508 Longhang Road, Shanghai, 201508, China. .,Department of Radiology, Nantong Cancer Hospital, Nantong University, 30 North Tongyang Road, Tongzhou District, Nantong, Jiangsu, 226361, China.
| | - Jin Wei Qiang
- Department of Radiology, Jinshan Hospital, Shanghai Medical College, Fudan University, 1508 Longhang Road, Shanghai, 201508, China.
| | - Gan Lin Xia
- Department of Radiology, Nantong Cancer Hospital, Nantong University, 30 North Tongyang Road, Tongzhou District, Nantong, Jiangsu, 226361, China.
| | - Shu Hui Zhao
- Department of Radiology, Xinhua Hospital, Shanghai Medical College, Jiaotong University, 1665 Kongjiang Road, Shanghai, 200092, China.
| | - Feng Hua Ma
- Department of Radiology, Jinshan Hospital, Shanghai Medical College, Fudan University, 1508 Longhang Road, Shanghai, 201508, China.
| | - Song Qi Cai
- Department of Radiology, Jinshan Hospital, Shanghai Medical College, Fudan University, 1508 Longhang Road, Shanghai, 201508, China.
| | - Feng Feng
- Department of Radiology, Nantong Cancer Hospital, Nantong University, 30 North Tongyang Road, Tongzhou District, Nantong, Jiangsu, 226361, China.
| | - Ai Yan Fu
- Department of Radiology, Nantong Cancer Hospital, Nantong University, 30 North Tongyang Road, Tongzhou District, Nantong, Jiangsu, 226361, China.
| |
Collapse
|
80
|
Fekonja A, Cretnik A, Zerdoner D, Takac I. Hypodontia phenotype in patients with epithelial ovarian cancer. Radiol Oncol 2015; 49:65-70. [PMID: 25810703 PMCID: PMC4362608 DOI: 10.2478/raon-2014-0034] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2013] [Accepted: 04/27/2014] [Indexed: 12/02/2022] Open
Abstract
BACKGROUND Ovarian cancer is usually diagnosed in an advanced stage and the present clinical and diagnostic molecular markers for early OC screening are insufficient. The aim of this study was to identify potential relationship between the hypodontia and epithelial ovarian cancer (EOC). PATIENTS AND METHODS A retrospective study was conducted on 120 patients with EOC treated at the Department of Gynaecologic and Breast Oncology at the University Clinical Centre and 120 gynaecological healthy women (control group) of the same mean age. Women in both groups were reviewed for the presence of hypodontia and the patients with EOC also for clinicopathological characteristics of EOC according to hypodontia phenotype. RESULTS Hypodontia was diagnosed in 23 (19.2%) of patients with EOC and 8 (6.7%) controls (p = 0.004; odds ratio [OR] = 3.32; confidence interval [CI], 1.42-7.76). There was no statistically significant difference in patients with EOC with or without hypodontia regarding histological subtype (p = 0.220); they differed in regard to FIGO stage (p = 0.014; OR =3.26; CI, 1.23-8.64) and tumour differentiation grade (p = 0.042; OR = 3.1; CI, 1.01-9.53). Also, bilateral occurrence of EOC was more common than unilateral occurrence in women with hypodontia (p = 0.021; OR = 2.9; CI, 1.15-7.36). We also found statistically significant difference between the ovarian cancer group and control group in presence of other malignant tumours in subjects (p < 0.001). CONCLUSIONS The results of the study suggest a statistical association between EOC and hypodontia phenotype. Hypodontia might serve as a risk factor for EOC detection.
Collapse
Affiliation(s)
- Anita Fekonja
- Department of Orthodontics, Health Centre Maribor, Maribor, Slovenia
| | - Andrej Cretnik
- Medical Faculty, University of Maribor, Maribor, Slovenia
| | - Danijel Zerdoner
- Medical Faculty, University of Maribor, Maribor, Slovenia
- Department of Maxillofacial and Oral Surgery, Teaching Hospital Celje, Celje, Slovenia
| | - Iztok Takac
- Medical Faculty, University of Maribor, Maribor, Slovenia
- Department of Gynaecologic and Breast Oncology, Clinical Department of Gynaecology and Perinatology, University Clinical Centre Maribor, Maribor, Slovenia
| |
Collapse
|
81
|
Tuna M, Ju Z, Smid M, Amos CI, Mills GB. Prognostic relevance of acquired uniparental disomy in serous ovarian cancer. Mol Cancer 2015; 14:29. [PMID: 25644622 PMCID: PMC4320828 DOI: 10.1186/s12943-015-0289-1] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2014] [Accepted: 01/04/2015] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND Acquired uniparental disomy (aUPD) can lead to homozygosity for tumor suppressor genes or oncogenes. Our purpose is to determine the frequency and profile aUPD regions in serous ovarian cancer (SOC) and investigated the association of aUPD with clinical features and patient outcomes. METHODS We analyzed single nucleotide polymorphism (SNP) array-based genotyping data on 532 SOC specimens from The Cancer Genome Atlas database to identify aUPD regions. Cox univariate regression and Cox multivariate proportional hazards analyses were performed for survival analysis. RESULTS We found that 94.7% of SOC samples harbored aUPD; the most common aUPD regions were in chromosomes 17q (76.7%), 17p (39.7%), and 13q (38.3%). In Cox univariate regression analysis, two independent regions of aUPD on chromosome 17q (A and C), and whole-chromosome aUPD were associated with shorter overall survival (OS), and five regions on chromosome 17q (A, D-G) and BRCA1 were associated with recurrence-free survival time. In Cox multivariable proportional hazards analysis, whole-chromosome aUPD was associated with shorter OS. One region of aUPD on chromosome 22q (B) was associated with unilateral disease. A statistically significant association was found between aUPD at TP53 loci and homozygous mutation of TP53 (p < 0.0001). CONCLUSIONS aUPD is a common event and some recurrent loci are associated with a poor outcome for patients with serous ovarian cancer.
Collapse
Affiliation(s)
- Musaffe Tuna
- Departments of Epidemiology, Unit 1340, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030-4009, USA.
| | - Zhenlin Ju
- Departments of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| | - Marcel Smid
- Department of Medical Oncology, Erasmus Medical Center - Daniel den Hoed Cancer Center, and Cancer Genomics Center, Rotterdam, The Netherlands.
| | - Christopher I Amos
- Departments of Epidemiology, Unit 1340, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030-4009, USA.
| | - Gordon B Mills
- Departments of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| |
Collapse
|
82
|
Che YL, Luo SJ, Li G, Cheng M, Gao YM, Li XM, Dai JM, He H, Wang J, Peng HJ, Zhang Y, Li WY, Wang H, Liu B, Linghu H. The C3G/Rap1 pathway promotes secretion of MMP-2 and MMP-9 and is involved in serous ovarian cancer metastasis. Cancer Lett 2015; 359:241-9. [PMID: 25617801 DOI: 10.1016/j.canlet.2015.01.019] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2014] [Revised: 12/26/2014] [Accepted: 01/16/2015] [Indexed: 11/16/2022]
Abstract
Complete resection is pivotal to improve survival to epithelial ovarian cancer (EOC). Crk SH3-domain-binding guanine nucleotide-releasing factor (C3G) is involved in multiple signaling pathways and it has opposite roles in different cancers. The present study aimed to identify C3G expression in ovarian tissue samples from patients with EOC and to explore its association with tumor grade. Eighty-seven archival paraffin-embedded, formalin-fixed, ovarian cancer tissues with serous histology were stained for C3G by immunohistochemistry. To evaluate the contribution of C3G to Rap1 activity, 36 patients with serous ovarian cancer (SOC) were investigated. Additionally, C3G was knocked down in SKOV3 and HEY cells. C3G regulated Rap1 activity and high Rap1 activity was correlated with poor differentiation, advanced FIGO stage, and unsuccessful cytoreductive surgery of SOC. Knockdown of C3G suppressed cell invasion, intravasation and extravasation, and reduced Rap1 activity and secretion of matrix metalloproteinase (MMP)-2 and MMP-9. C3G-mediated activation of Rap1 could direct the tumor pattern of human SOC by promoting the secretion of MMP-2 and MMP-9. These results suggest that C3G is involved in the metastatic spread of EOC.
Collapse
Affiliation(s)
- Ya-Ling Che
- Department of Obstetrics and Gynecology, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China; Department of Obstetrics & Gynecology, Central Hospital of Xi'an, Xi'an 710003, China
| | - Shu-Juan Luo
- Department of Obstetrics and Gynecology, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China; Department of Obstetrics & Gynecology, Maternal and Child Care Service Centre of Chongqing, Chongqing 400016, China
| | - Gang Li
- Department of Geriatrics, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - Min Cheng
- Department of Obstetrics and Gynecology, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - Yi-Meng Gao
- Department of Obstetrics and Gynecology, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - Xue-Mei Li
- Department of Obstetrics and Gynecology, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - Jie-Min Dai
- Department of Obstetrics and Gynecology, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - Huan He
- Department of Obstetrics and Gynecology, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - Jin Wang
- Department of Obstetrics and Gynecology, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - Hui-Juan Peng
- Department of Obstetrics and Gynecology, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - Yu Zhang
- Department of Obstetrics and Gynecology, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - Wen-Yan Li
- Department of Obstetrics and Gynecology, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - Hui Wang
- Department of Obstetrics and Gynecology, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - Bin Liu
- Department of Pathology, Basic Medical School of Chongqing Medical University, Chongqing 400016, China
| | - Hua Linghu
- Department of Obstetrics and Gynecology, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
| |
Collapse
|
83
|
Fekonja A, Čretnik A, Takač I. Hypodontia prevalence and pattern in women with epithelial ovarian cancer. Angle Orthod 2014; 84:810-4. [PMID: 24689849 PMCID: PMC8641280 DOI: 10.2319/112813-876.1] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2013] [Accepted: 01/01/2014] [Indexed: 11/23/2022] Open
Abstract
OBJECTIVE To analyze the possible association between hypodontia and epithelial ovarian cancer (EOC), with the special interest in hypodontia pattern. MATERIALS AND METHODS One hundred twenty women with EOC treated at the Department of Gynecologic and Breast Oncology at the University Clinical Centre and 120 gynecologically healthy women of the same average age were reviewed for the presence and pattern of hypodontia. Collected data were analyzed for frequency, tooth type, location per jaw and side, number of missing teeth per person, and family history of hypodontia. RESULTS The results of the study showed prevalence of hypodontia in 19.2% of women with EOC and in 6.7% of women in the control group (P = .004). The most frequently missing teeth for women with EOC and women in the control group were maxillary second premolars and maxillary lateral incisors, respectively. Unilateral occurrence of hypodontia was more common than bilateral occurrence in women with EOC (P = .034). Of women with EOC and hypodontia, 21.7% reported a positive family history of hypodontia compared with no report in the control group of women with hypodontia (P = .150). CONCLUSIONS The results statistically support possible association between EOC and hypodontia. Because hypdontia can be recognized early in life, this finding could possibly help in earlier detection of EOC, resulting in better prognosis and treatment in earlier stages of the disease. Earlier EOC diagnosis and treatment could save many lives.
Collapse
Affiliation(s)
- Anita Fekonja
- Department Head, Department of Orthodontics, Health Centre Maribor, Maribor, Slovenia
| | - Andrej Čretnik
- Associate Professor, Medical Faculty, University of Maribor, Maribor, Slovenia
| | - Iztok Takač
- Professor and Department Head, Department of Gynecologic and Breast Oncology, Clinical Department of Gynecology and Perinatology, University Clinical Centre Maribor, Medical Faculty, University of Maribor, Maribor, Slovenia
| |
Collapse
|
84
|
Adham SAI, Al Harrasi I, Al Haddabi I, Al Rashdi A, Al Sinawi S, Al Maniri A, Ba-Omar T, Coomber BL. Immunohistological insight into the correlation between neuropilin-1 and epithelial-mesenchymal transition markers in epithelial ovarian cancer. J Histochem Cytochem 2014; 62:619-31. [PMID: 24850663 DOI: 10.1369/0022155414538821] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
The mechanism by which neuropilin-1 (NRP-1) induces malignancy in Epithelial Ovarian Cancer (EOC) is still unknown. This study is the first to demonstrate the relationship between NRP-1 expression and EMT markers vimentin, N-cadherin, E-cadherin and Slug. We used tissue microarrays containing the three main subtypes of EOC tumors: serous, mucinous cystadenocarcinoma and endometrioid adenocarcinoma and representative cases retrieved from our pathology archives. Immunohistochemistry was performed to detect the expression levels and location of NRP-1 and the aforementioned EMT proteins. NRP-1 was mainly expressed on cancer cells but not in normal ovarian surface epithelium (OSE). The Immunoreactive Scoring (IRS) values revealed that the expression of NRP-1, Slug and E-cadherin in the malignant subtypes of ovarian tissues was significantly higher (5.18 ± 0.64, 4.84 ± 0.7, 4.98 ± 0.68, respectively) than their expression in the normal and benign tissues (1.04 ± 0.29, 0.84 ± 0.68, 1.71 ± 0.66, respectively), with no significant differences among the studied subtypes. Vimentin was expressed in the cancer cell component of 43% of tumors and it was exclusively localized in the stroma of all mucinous tumors. The Spearman's rho value indicated that NRP-1 is positively related to the EMT markers E-cadherin and Slug. This notion might indicate that NRP-1 is a partner in the EMT process in EOC tumors.
Collapse
Affiliation(s)
- Sirin A I Adham
- Department of Biology, College of Science (SAIA, IAH, TBO) Sultan Qaboos University, Muscat, OmanDepartment of Pathology, College of Medicine (IAH, AAR, SAS) Sultan Qaboos University, Muscat, OmanThe Research Council, Muscat, Oman (AAM)Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada (BLC)
| | - Ibtisam Al Harrasi
- Department of Biology, College of Science (SAIA, IAH, TBO) Sultan Qaboos University, Muscat, OmanDepartment of Pathology, College of Medicine (IAH, AAR, SAS) Sultan Qaboos University, Muscat, OmanThe Research Council, Muscat, Oman (AAM)Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada (BLC)
| | - Ibrahim Al Haddabi
- Department of Biology, College of Science (SAIA, IAH, TBO) Sultan Qaboos University, Muscat, OmanDepartment of Pathology, College of Medicine (IAH, AAR, SAS) Sultan Qaboos University, Muscat, OmanThe Research Council, Muscat, Oman (AAM)Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada (BLC)
| | - Afrah Al Rashdi
- Department of Biology, College of Science (SAIA, IAH, TBO) Sultan Qaboos University, Muscat, OmanDepartment of Pathology, College of Medicine (IAH, AAR, SAS) Sultan Qaboos University, Muscat, OmanThe Research Council, Muscat, Oman (AAM)Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada (BLC)
| | - Shadia Al Sinawi
- Department of Biology, College of Science (SAIA, IAH, TBO) Sultan Qaboos University, Muscat, OmanDepartment of Pathology, College of Medicine (IAH, AAR, SAS) Sultan Qaboos University, Muscat, OmanThe Research Council, Muscat, Oman (AAM)Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada (BLC)
| | - Abdullah Al Maniri
- Department of Biology, College of Science (SAIA, IAH, TBO) Sultan Qaboos University, Muscat, OmanDepartment of Pathology, College of Medicine (IAH, AAR, SAS) Sultan Qaboos University, Muscat, OmanThe Research Council, Muscat, Oman (AAM)Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada (BLC)
| | - Taher Ba-Omar
- Department of Biology, College of Science (SAIA, IAH, TBO) Sultan Qaboos University, Muscat, OmanDepartment of Pathology, College of Medicine (IAH, AAR, SAS) Sultan Qaboos University, Muscat, OmanThe Research Council, Muscat, Oman (AAM)Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada (BLC)
| | - Brenda L Coomber
- Department of Biology, College of Science (SAIA, IAH, TBO) Sultan Qaboos University, Muscat, OmanDepartment of Pathology, College of Medicine (IAH, AAR, SAS) Sultan Qaboos University, Muscat, OmanThe Research Council, Muscat, Oman (AAM)Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada (BLC)
| |
Collapse
|
85
|
Wang Y, Li L, Qu Z, Li R, Bi T, Jiang J, Zhao H. The expression of miR-30a* and miR-30e* is associated with a dualistic model for grading ovarian papillary serious carcinoma. Int J Oncol 2014; 44:1904-14. [PMID: 24676806 DOI: 10.3892/ijo.2014.2359] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2013] [Accepted: 12/27/2013] [Indexed: 11/06/2022] Open
Abstract
Histological grade has already been recognized as a very important prognostic factor for ovarian papillary serous carcinoma (OPSC). On the basis of pathogenetic mechanisms, recent findings suggest a dualistic model of OPSC consisting of types I (low-grade) and II (high-grade) cancers. High-grade OPSC is responsible for most ovarian cancer deaths. The goal of our investigation was to identify the differences in key miRNAs and possible regulators through miRNA microarray chip analysis, as well as functional target prediction and clinical outcome between the low and high-grade OPSC patients. The pathogenic basis in differentiation of ovarian cancer subtypes was studied to provide insight into diagnosis and therapy for high-grade cases. Through microarray analysis, we found that miR-30a* and miR-30e* were the top 2 significantly different miRNAs between type I and type II OPSC patients, and both were remarkably downregulated in the latter type. ATF3 and MYC were indicated as potential co-targets of miR-30a* and miR-30e*, and showed a significant upregulation in type II patients. As ATF3 and MYC are often associated with aggressive behavior and poor differentiation, especially in human cancers, these results are in good agreement with our findings and point toward a regulating differentiation function of the miR-30a* and miR-30e* genes. Further analysis using leave‑one-out cross predictions and Kaplan-Meier survival analysis strongly suggested that miR-30a* and miR-30e* can be used as biomarkers to tailor histological grade before starting the regimen, and they showed important roles in ovarian cancer differentiation resulting in poorer prognosis. In general, miR-30a* and miR-30e* coupled with expression data that reveal pathogenic regulation to predict histological differentiation, may operate to direct the formation of early detection and therapeutic approaches to individual OPSC patients, especially differentiation therapy to high-grade cases.
Collapse
Affiliation(s)
- Yan Wang
- Laboratory Center, Second Affiliated Hospital of Dalian Medical University, Dalian, P.R. China
| | - Lv Li
- Department of Pathology, Second Affiliated Hospital of Dalian Medical University, Dalian, P.R. China
| | - Zhenyun Qu
- Department of Pathophysiology, Dalian Medical University, Dalian, P.R. China
| | - Ruomeng Li
- Department of Anesthesiology, Second Affiliated Hospital of Dalian Medical University, Dalian, P.R. China
| | - Tie Bi
- Obstetrics and Gynecology Hospital, Dalian, P.R. China
| | - Jiyong Jiang
- Obstetrics and Gynecology Hospital, Dalian, P.R. China
| | - Henan Zhao
- Department of Pathophysiology, Dalian Medical University, Dalian, P.R. China
| |
Collapse
|
86
|
Cho H, Cho CS, Indig GL, Lavasanifar A, Vakili MR, Kwon GS. Polymeric micelles for apoptosis-targeted optical imaging of cancer and intraoperative surgical guidance. PLoS One 2014; 9:e89968. [PMID: 24587157 PMCID: PMC3935963 DOI: 10.1371/journal.pone.0089968] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2013] [Accepted: 01/23/2014] [Indexed: 01/07/2023] Open
Abstract
In a two-step strategy, an intraperitoneal (IP) injection of poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-b-PCL) micelles containing paclitaxel (PTX), cyclopamine (CYP), and gossypol (GSP) at 30, 30, and 30 mg/kg, respectively, debulked tumor tissues by 1.3-fold, based on loss of bioluminescence with <10% body weight change, and induced apoptosis in peritoneal tumors when used as neoadjuvant chemotherapy (NACT) in an ES-2-luc-bearing xenograft model for ovarian cancer. In a second step, a single intravenous (IV) injection of apoptosis-targeting GFNFRLKAGAKIRFGS-PEG-b-PCL micelles containing a near-infrared (NIR) fluorescence probe, DiR (1,1′-dioctadecyltetramethyl indotricarbocyanine iodide), resulted in increased peritoneal DiR accumulation in apoptosis-induced ES-2-luc tumor tissues (ex vivo) by 1.5-fold compared with DiR molecules delivered by methoxy PEG-b-PCL micelles (non-targeted) at 48 h after IV injection in a second step. As a result, a tandem of PEG-b-PCL micelles enabled high-resolution detection of ca. 1 mm diameter tumors, resulting in resection of approximately 90% of tumors, and a low peritoneal cancer index (PCI) of ca. 7. Thus, a tandem of PEG-b-PCL micelles used for NCAT and NIR fluorescence imaging of therapy-induced apoptosis for intraoperative surgical guidance may be a promising treatment strategy for metastatic ovarian cancer.
Collapse
Affiliation(s)
- Hyunah Cho
- Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin, Madison, Wisconsin, United States of America
| | - Clifford S. Cho
- Section of Surgical Oncology, Department of Surgery, University of Wisconsin, Madison, Wisconsin, United States of America
| | - Guilherme L. Indig
- Department of Chemistry and Biochemistry, University of Wisconsin, Milwaukee, Wisconsin, Unites States of America
| | - Afsaneh Lavasanifar
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
| | - Mohammad Reza Vakili
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
| | - Glen S. Kwon
- Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin, Madison, Wisconsin, United States of America
- * E-mail:
| |
Collapse
|
87
|
Xiao X, Melton DW, Gourley C. Mismatch repair deficiency in ovarian cancer — Molecular characteristics and clinical implications. Gynecol Oncol 2014; 132:506-12. [DOI: 10.1016/j.ygyno.2013.12.003] [Citation(s) in RCA: 54] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2013] [Revised: 11/26/2013] [Accepted: 12/02/2013] [Indexed: 01/24/2023]
|
88
|
Lum CT, Wai-Yin Sun R, Zou T, Che CM. Gold(iii) complexes inhibit growth of cisplatin-resistant ovarian cancer in association with upregulation of proapoptotic PMS2 gene. Chem Sci 2014. [DOI: 10.1039/c3sc53203h] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
|
89
|
Abstract
BRAF represents one of the most frequently mutated protein kinase genes in human tumours. The mutation is commonly tested in pathology practice. BRAF mutation is seen in melanoma, papillary thyroid carcinoma (including papillary thyroid carcinoma arising from ovarian teratoma), ovarian serous tumours, colorectal carcinoma, gliomas, hepatobiliary carcinomas and hairy cell leukaemia. In these cancers, various genetic aberrations of the BRAF proto-oncogene, such as different point mutations and chromosomal rearrangements, have been reported. The most common mutation, BRAF V600E, can be detected by DNA sequencing and immunohistochemistry on formalin fixed, paraffin embedded tumour tissue. Detection of BRAF V600E mutation has the potential for clinical use as a diagnostic and prognostic marker. In addition, a great deal of research effort has been spent in strategies inhibiting its activity. Indeed, recent clinical trials involving BRAF selective inhibitors exhibited promising response rates in metastatic melanoma patients. Clinical trials are underway for other cancers. However, cutaneous side effects of treatment have been reported and therapeutic response to cancer is short-lived due to the emergence of several resistance mechanisms. In this review, we give an update on the clinical pathological relevance of BRAF mutation in cancer. It is hoped that the review will enhance the direction of future research and assist in more effective use of the knowledge of BRAF mutation in clinical practice.
Collapse
|
90
|
Wan SM, Peng P, Guan T. Ets-1 regulates its target genes mainly by DNA methylation in human ovarian cancer. J OBSTET GYNAECOL 2013; 33:877-81. [DOI: 10.3109/01443615.2013.820268] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
91
|
Proteomic Analysis of Matched Formalin-Fixed, Paraffin-Embedded Specimens in Patients with Advanced Serous Ovarian Carcinoma. Proteomes 2013; 1:240-253. [PMID: 28250404 PMCID: PMC5302701 DOI: 10.3390/proteomes1030240] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2013] [Revised: 10/08/2013] [Accepted: 10/08/2013] [Indexed: 01/01/2023] Open
Abstract
OBJECTIVE The biology of high grade serous ovarian carcinoma (HGSOC) is poorly understood. Little has been reported on intratumoral homogeneity or heterogeneity of primary HGSOC tumors and their metastases. We evaluated the global protein expression profiles of paired primary and metastatic HGSOC from formalin-fixed, paraffin-embedded (FFPE) tissue samples. METHODS After IRB approval, six patients with advanced HGSOC were identified with tumor in both ovaries at initial surgery. Laser capture microdissection (LCM) was used to extract tumor for protein digestion. Peptides were extracted and analyzed by reversed-phase liquid chromatography coupled to a linear ion trap mass spectrometer. Tandem mass spectra were searched against the UniProt human protein database. Differences in protein abundance between samples were assessed and analyzed by Ingenuity Pathway Analysis software. Immunohistochemistry (IHC) for select proteins from the original and an additional validation set of five patients was performed. RESULTS Unsupervised clustering of the abundance profiles placed the paired specimens adjacent to each other. IHC H-score analysis of the validation set revealed a strong correlation between paired samples for all proteins. For the similarly expressed proteins, the estimated correlation coefficients in two of three experimental samples and all validation samples were statistically significant (p < 0.05). The estimated correlation coefficients in the experimental sample proteins classified as differentially expressed were not statistically significant. CONCLUSION A global proteomic screen of primary HGSOC tumors and their metastatic lesions identifies tumoral homogeneity and heterogeneity and provides preliminary insight into these protein profiles and the cellular pathways they constitute.
Collapse
|
92
|
Nodin B, Zendehrokh N, Sundström M, Jirström K. Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer. Diagn Pathol 2013; 8:106. [PMID: 23800114 PMCID: PMC3722044 DOI: 10.1186/1746-1596-8-106] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2013] [Accepted: 06/12/2013] [Indexed: 01/09/2023] Open
Abstract
Background Activating KRAS mutations are common in ovarian carcinomas of low histological grade, less advanced clinical stage and mucinous histological subtype, and form part of the distinct molecular alterations associated with type I tumors in the dualistic model of ovarian carcinogenesis. Here, we investigated the occurrence, clinicopathological correlates and prognostic significance of specific KRAS mutations in tumours from 153 epithelial ovarian cancer (EOC) cases from a pooled, prospective cohort. Methods KRAS codon 12,13 and 61 mutations were analysed by pyrosequencing in tumours from 163 incident EOC cases in the Malmö Diet and Cancer Study and Malmö Preventive Project. Associations of mutational status with clinicopathological and molecular characteristics were assessed by Pearson Chi Square test. Ovarian cancer-specific survival (OCSS) according to mutational status was explored by Kaplan-Meier analysis and Cox proportional hazards modelling. KRAS-mutation status was also analysed in 28 concomitantly sampled benign-appearing fallopian tubes. Results Seventeen (11.1%) EOC cases harboured mutations in the KRAS gene, all but one in codon 12, and one in codon 13. No KRAS mutations were found in codon 61 and all examined fallopian tubes were KRAS wild-type. KRAS mutation was significantly associated with lower grade (p = 0.001), mucinous histological subtype (p = < 0.001) and progesterone receptor expression (p = 0.035). Kaplan-Meier analysis revealed a significantly improved OCSS for patients with KRAS-mutated compared to KRAS wild-type tumours (p = 0.015). These associations were confirmed in unadjusted Cox regression analysis (HR = 2.51; 95% CI 1.17-5.42) but did not remain significant after adjustment for age, grade and clinical stage. The beneficial prognostic impact of KRAS mutation was ony evident in tumours of low-intermediate differentiation grade (p = 0.023), and in a less advanced clinical stage (p = 0.014). Moreover, KRAS mutation was associated with a significantly improved OCSS in the subgroup of endometroid carcinomas (p = 0.012). Conclusions The results from this study confirm previously demonstrated associations of KRAS mutations with well-differentiated and mucinous ovarian carcinomas. Moreover, KRAS-mutated tumours had a significantly improved survival in unadjusted, but not adjusted, analysis. A finding that merits further study is the significant prognostic impact of KRAS mutation in endometroid carcinomas, potentially indicating that response to Ras/Raf/MEK/ERK-targeting therapies may differ by histological subtype. Virtual slides The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1788330379100147
Collapse
Affiliation(s)
- Björn Nodin
- Department of Clinical Sciences, Division of Pathology, Lund University, Skåne University Hospital, Lund, Sweden.
| | | | | | | |
Collapse
|
93
|
Clinical and Ultrasound Features of Type I and Type II Epithelial Ovarian Cancer. Int J Gynecol Cancer 2013; 23:680-4. [DOI: 10.1097/igc.0b013e31828bdbb6] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
94
|
Ma SH, Kim BG, Choi JY, Kim TJ, Kim YM, Kim JW, Kang S, Kang D, Yoo KY, Park SK. Korean epithelial ovarian cancer study (Ko-EVE): protocols and interim report. Asian Pac J Cancer Prev 2013; 13:3731-40. [PMID: 23098463 DOI: 10.7314/apjcp.2012.13.8.3731] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND There have been few studies of Asian ovarian cancer and benign tumors. The primary aim of this paper was to report the protocol of the Ko-EVE study to examine epidemiological and molecular factors for ovarian cancer and benign neoplasms and to ascertain the major risk factors for ovarian cancer control in Korea. METHODS This case-control study covers incident epithelial ovarian cancers and benign neoplasms, four major centers participating in enrolling incident cases and 3 hospitals enrolling healthy controls among health examinees. Standardized questionnaires were administered by trained interviewers, including sections on socio-demographics characteristics, past medical history, medication usage, family history, lifetime consumption of alcohol and tobacco, diet, physical activity, and reproductive factors for women. Various biological specimens were collected in the biorepository according to the standardized protocol. Annual follow-up for cancer cases and follow-up at the 1st year for benign tumor cases are performing to evaluate treatment effect and progression. Passive follow to see long-term survival will be conducting using record linkage with national data. RESULTS The total number recruited in 2010-2011 was 246 epithelial ovarian cancer cases, 362 benign epithelial tumors and 345 controls. We are planning to collect subjects for at least 1,500 sets of ovarian cancer, 2,000 benign tumors and 1,500 controls till 2018. CONCLUSION The Ko-EVE will provide unique and important data to probe the etiology and natural history of Korean epithelial ovarian cancer. It will be continued by genomic and proteomic epidemiological analyses and future intervention studies for the prevention of ovarian cancer among Koreans.
Collapse
Affiliation(s)
- Seung Hyun Ma
- Department of Preventive Medicine, College of Medicine, Seoul National University, Seoul, Korea
| | | | | | | | | | | | | | | | | | | |
Collapse
|
95
|
A Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted Therapies. Int J Mol Sci 2013; 14:6067-73. [PMID: 23502469 PMCID: PMC3634399 DOI: 10.3390/ijms14036067] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2013] [Revised: 03/11/2013] [Accepted: 03/12/2013] [Indexed: 12/27/2022] Open
Abstract
Ovarian cancer treatment presently does not reflect molecular differences in histologic subtype. Ovarian clear cell carcinoma (OCCC) exhibits several differences in terms of molecular pathogenesis and tumor behavior from the more common, chemosensitive, serous carcinomas, which makes OCCC a candidate for targeted therapies. A 53-year-old Japanese woman was diagnosed with stage IIIc ovarian clear cell adenocarcinoma with marked chemoresistance to conventional regimens. She demonstrated a partial response to a multikinase inhibitor. The tumor was resistant to PI3K/mTOR pathway inhibitors despite harboring a PIK3CA mutation. The present case suggests a role for targeted therapies in the treatment of OCCC and a need for the identification of biomarkers that will predict response to targeted therapies.
Collapse
|
96
|
DUAN JIE, LANG YAN, SONG CHENGWEN, XIONG JUN, WANG YAN, YAN YANG. siRNA targeting of PRDX3 enhances cisplatin-induced apoptosis in ovarian cancer cells through the suppression of the NF-κB signaling pathway. Mol Med Rep 2013; 7:1688-94. [DOI: 10.3892/mmr.2013.1370] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2012] [Accepted: 03/05/2013] [Indexed: 11/06/2022] Open
|
97
|
Ojili V, Tirumani SH, Chintapalli KN, Gunabushanam G. Non-Invasive Diagnosis of Abdomino-Pelvic Masses: Role of Multimodality Imaging. J Clin Imaging Sci 2013; 3:6. [PMID: 23607075 PMCID: PMC3625888 DOI: 10.4103/2156-7514.106621] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2012] [Accepted: 12/18/2012] [Indexed: 11/04/2022] Open
Abstract
Recent advances in radiology have greatly increased the ability to make highly accurate diagnosis. Biopsy of many commonly seen lesions is no longer performed as the radiological findings are pathognomonic. This gives rise to the concept of ‘virtual biopsy’, a term coined on the lines of other imaging techniques such as virtual colonoscopy. Virtual biopsy is not a new imaging technique but a new concept which refers to the use of existing imaging modalities to evaluate the morphological features of tumors and arriving at a non-invasive diagnosis with a high degree of confidence obviating the need for true biopsy. Elements of virtual biopsy have already been incorporated into some evidence-based guidelines, and it is expected that with further technological advancements, an increasing number of tumors may be diagnosed and managed accordingly. A wider acceptance of virtual biopsy could further reduce the need for invasive biopsies and its attendant costs and risks. In this review article, we use index cases to further emphasize this concept.
Collapse
Affiliation(s)
- Vijayanadh Ojili
- Department of Radiology, University of Texas Health Sciences Centre at San Antonio, San Antonio, TX 78229, USA
| | - Sree Harsha Tirumani
- Department of Imaging, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
| | - Kedar N. Chintapalli
- Department of Radiology, University of Texas Health Sciences Centre at San Antonio, San Antonio, TX 78229, USA
| | - Gowthaman Gunabushanam
- Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, Connecticut, 06520-8042, USA
| |
Collapse
|
98
|
Cho H, Lai TC, Kwon GS. Poly(ethylene glycol)-block-poly(ε-caprolactone) micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer. J Control Release 2012; 166:1-9. [PMID: 23246471 DOI: 10.1016/j.jconrel.2012.12.005] [Citation(s) in RCA: 74] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2012] [Revised: 11/27/2012] [Accepted: 12/04/2012] [Indexed: 12/31/2022]
Abstract
Ovarian cancer is the most lethal gynecological malignancy, characterized by a high rate of chemoresistance. Current treatment strategies for ovarian cancer focus on novel drug combinations of cytotoxic agents and molecular targeted agents or novel drug delivery strategies that often involve intraperitoneal (IP) injection. Poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-b-PCL) micelles were loaded with paclitaxel (cytotoxic agent), cyclopamine (hedgehog inhibitor), and gossypol (Bcl-2 inhibitor). After physicochemical studies focusing on combination drug solubilization, 3-drug PEG-b-PCL micelles were evaluated in vitro in 2-D and 3-D cell culture and in vivo in xenograft models of ovarian cancer, tracking bioluminescence signals from ES-2 and SKOV3 human ovarian cancer cell lines after IP injection. 3-Drug PEG-b-PCL micelles were not significantly more potent in 2-D cell culture in comparison to paclitaxel; however, they disaggregated ES-2 tumor spheroids, whereas single drugs or 2-drug combinations only slowed growth of ES-2 tumor spheroids or had no noticeable effects. In ES-2 and SKOV3 xenograft models, 3-drug PEG-b-PCL micelles had significantly less tumor burden than paclitaxel based on bioluminescence imaging, 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) PET imaging, and overall survival. (18)F-FLT-PET images clearly showed that 3-drug PEG-b-PCL micelles dramatically reduce tumor volumes over paclitaxel and vehicle controls. In summary, PEG-b-PCL micelles enable the IP combination drug delivery of paclitaxel, cyclopamine and gossypol, resulting in tumor growth inhibition and prolonged survival over paclitaxel alone. These results validate a novel treatment strategy for ovarian cancer based on drug combinations of cytotoxic agents and molecular targeted agents, delivered concurrently by a nanoscale drug delivery system, e.g. PEG-b-PCL micelles.
Collapse
Affiliation(s)
- Hyunah Cho
- Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin, Madison, WI 53705, USA
| | | | | |
Collapse
|
99
|
Guruprasad B, Jacob LA. Mucinous cystadenocarcinoma of ovary: Changing treatment paradigms. World J Obstet Gynecol 2012; 1:42-45. [DOI: 10.5317/wjog.v1.i4.42] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Traditionally, all carcinomas arising from the surface epithelial layer of the ovary have been grouped together. This grouping has led to a single therapeutic strategy that is used for all epithelial ovarian cancers. However mucinous cancers appear to be distinct from serous cancers in their clinical behaviour and molecular signatures. In comparison to serous tumours, early stage mucinous tumours tend to be localised at diagnosis with a higher overall survival. But when metastatic at presentation or after recurrence, the outcome of mucinous tumours is far inferior to serous tumours. With standard platinum based chemotherapy the response rate and survival is far worse in mucinous cancers. The precise biological and molecular explanation for this difference remains unanswered. There is urgent need for testing and adoption of therapeutic approaches tailored to molecular characteristics of mucinous carcinomas so that patient survival can be optimised.
Collapse
|
100
|
Zhu C, Pinsky P, Berg C. Improving Research on Biomarkers for Early Detection and Screening of Cancers. Cancer Biomark 2012. [DOI: 10.1201/b14318-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|